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ABSTRACT 
Vitamin B-6 (B-6), an essential nutrient whose coenzyme form pyridoxal 
5'-phosphate (PLP) is required by over 100 enzymes, is involved in various metabolic 
processes including glycogenolysis, niacin synthesis, lipid metabolism, erythrocyte function, 
nervous system function, hormone modulation, immune function, and one-carbon 
metabolism. Pyridoxine glucoside (PNG), a less bioavailable form compared with other 
forms of B-6, is present in plant foods and absent in animal foods. With the recognition of 
health effects of soy, such as its cholesterol-lowering effect, there has been an increase in 
soyfoods consumption. Middle aged women frequently have marginal intakes of B-6, and 
many drink soymilk for its purported benefit in relieving menopausal symptoms. Although 
the PNG content of soymilk has not been reported, PNG content of other soyfoods ranges 
from 57-67% of the total B-6. The effect of substituting soymilk for cow's milk on B-6 status 
was examined in middle aged women (aged 36-52 y; n = 16). The study employed a 
crossover design: a 14-d adjustment period followed by a 28-d experimental period, during 
which half the subjects consumed 4 cups of cow's milk and half consumed 4 cups of soymilk 
per day; a 14-d washout period and a second 28-d experimental period when subjects 
switched to the other milk. Participants followed aself-selected B-6 restricted diet (~1 mg/d) 
throughout the study by following a list of prohibited or restricted foods. Three consecutive 
24-h urine samples were collected and fasting blood was drawn every two weeks. Methionine 
loads (0.1 g/kg body weight) were given at the end of each experimental period. Plasma PLP, 
4-pyridoxic acid (4-PA), urinary 4-PA, and pre- and postload plasma homocysteine were 
determined by HPLC analysis. Using crossover ANOVA tests, mean plasma 4-PA (P = 0.001), 
and urinary 4-PA-to-creatinine ratio (P < 0.001) were significantly lower when soymilk was 
consumed. There was no evidence that the mean plasma PLP (P = 0.107) and the increase in 
mean plasma total homocysteine concentrations after a methionine load (P = 0.316} were 
different between the cow's milk and soymilk treatments. We may have reported significant 
effects during the soymilk versus cow's milk treatment if the study period was longer (>28 d), 
the diets more rigidly controlled, and our sample size was larger (n > 16) regarding these two 
measures. These results suggest that substituting soymilk for cow's milk has an adverse 
X 
effect on B-6 status in middle aged Women as reflected by the reduced status indicators after 
soymilk treatment. 
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CHAPTER 1. INTRODUCTION 
Thesis Organization 
The content of this thesis is organized into several chapters. The first chapter includes 
the organization of the thesis and an introduction to the overall research questions addressed. 
Chapter 2 is a review of the literature including information that is relevant to the research 
reported here concerning vitamin B-6 metabolism, bioavailability, and status assessment. 
Chapters 3 and 4 contain the study regarding the effect of substituting soymilk for cow's milk 
on B-6 status in middle aged women (aged 36-52 y; n = 16) including methods, results, and 
discussion. Summary and conclusions constitute Chapter 5, followed by an Appendix that 
provides raw data tables and forms, as well as the complete list of the literature cited 
throughout this thesis. 
Description of the Research Questions 
Vitamin B-6 (B-6) via its coenzyme form pyridoxal 5'-phosphate (PLP) plays an 
important role in various metabolic processes. Pyridoxine glucoside (PNG), the less 
bioavailable form compared with other B-6 forms, has been found to comprise up to 80% of 
B-6 in plant foods and is absent in animal foods (Kabir H et al. 1983; Gregory and Ink 1987). 
It has been shown that PNG is not interconvertible with other B-6 vitamers until its 
glucosidic bond is cleaved (Gregory 1997). Because approximately half of the dietary 
vitamin B-6 intake of Americans is from plant sources (Kant and Block 1990), studies 
addressing PNG bioavailability in vivo have drawn more attention. Human feeding studies 
comparing B-6 bioavailability in foods with their relative PNG content indicated an inverse 
relationship between PNG content and bioavailability (Kabir et al. 1983). Hansen et al. 
(1996b) reported that in a controlled study, the bioavailability of PNG is incomplete and of 
sufficient magnitude to affect nutritional status. Moreover, apart from its partial 
bioavailability, PNG was found weakly antagonistic to the utilization of nonglycosylated 
forms of the vitamin in mammals (Gregory 1998). 
With the recognition of the health effects of soy, such as a health claim approved by 
the Food and Drug Administration (FDA) in 1999 that soy protein reduces the risk of 
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coronary heart disease by lowering blood cholesterol, there has been an increase in soyfoods 
consumption (Messina et al. 2002). However, there is limited information about the forms of 
vitamin B-6 in commercially available soyfoods and soy protein products that have not been 
fortified with vitamin B-6. The effect of substituting unfortified soy products for animal 
products on vitamin B-6 status has not been investigated. 
It has been found that middle age women (ages 35-55 y) frequently have marginal 
intakes of vitamin B-6 (Institute of Medicine 1998), and many drink soymilk for its 
purported beneficial effect in alleviating menopausal symptoms (Kronenberg and 
Fugh-Berman 2002). There has been limited information regarding the PNG content in 
soymilk. Moreover, a study in rats showed apart from the effect of PNG content in soy, 
replacing animal protein with soy protein might have an additional adverse effect on B-6 
status (Lu and Huang 1997). Based on the aforementioned evidence, the goal of our study 
was to determine the effect of substituting soymilk for cow's milk on vitamin B-6 status in 
middle aged women. 
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CHAPTER 2. LITERATURE REVIEW AND RATIONALE 
Introduction 
Vitamin B-6, awater-soluble essential nutrient, is composed of a group of six 
interconvertable compounds (B-6 vitamers) related chemically, metabolically, and 
functionally. All six B-6 vitamers are derivatives of 3-hydroxy-5-hydroxymethyl-2-methyl 
pyridine that can mimic the biological activity of pyridoxine. The three naturally occurring 
compounds of vitamin B-6 are pyridoxine (PN), pyridoxal (PL), and pyridoxamine (PM), and 
their respective phosphorylated derivatives are pyridoxine 5'-phosphate (PNP), pyridoxal 
5'-phosphate (PLP), and pyridoxamine 5'-phosphate (PMP) (Leklem 1999). 
In 1934, Paul Gyorgy first used the term "vitamin B-6" to designate the substance in 
crude feed supplement that later on proved to be able to heal a florid dermatitis that occurred 
in rats fed a purified diet supplemented with vitamins B-1 and B-2; subsequently, he named 
the substance pyridoxine (Esmond 1981; Holman 1995). Several groups in 1938 isolated 
vitamin B-6 in crystalline form identified as 3-hydroxy-5-hydroxymethyl-2-methyl pyridine 
(Esmond 1981; Holman 1995; Leklem 1999). 
Our understanding of the various roles vitamin B-6 plays has been advanced 
significantly since its discovery and identification of its structure some 70 years ago. Vitamin 
B-6 is essential in the metabolism of amino acid metabolism: it is involved in transamination, 
decarboxylation, and a variety of elimination and replacement reactions (Bender 1992). 
Vitamin B-6 may have a potential role in the treatment of various chronic and genetic 
diseases including cancer, asthma, Down's syndrome, sickle cell anemia, and coronary heart 
disease (Leklem 2001). The major coenzyme form, PLP, is required by over 100 enzymes in 
diverse metabolic processes including glycogenolysis, niacin synthesis, lipid metabolism, 
erythrocyte function, nervous system function, hormone modulation, immune function, and 
one-carbon metabolism (Leklem 1999). The major forms of vitamin B-6 present in animal 
products are PLP and PMP, which are active coenzyme forms, with PLP being the primary 
form of biologic interest. In plant-derived foods, the principal forms of vitamin B-6 are PN, 
PNP, and pyridoxine-l3-D-glucoside (PNG) (Leklem 1999). Moreover, PNG, the conjugated 
form of vitamin B-6, is virtually absent in animal products (Leklem 1999). The catabolic end 
product of vitamin B-6 in the liver is 4-pyridoxic acid (4-PA), which excreted in the urine 
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(Leklem 2001). Urinary 4-PA excretion accounts for 40-60% of daily vitamin B-6 intake in 
individuals consuming 1-5 mg of the vitamin daily (Leklem 2001). Under normal dietary 
conditions, the predominant form of vitamin B-6 in human plasma is PLP, which makes up 
50-75% of the total, and PL comprises approximately 8-30% of the total, followed by lower 
concentrations of PN, PMP, and PM (Leklem 2001). Pyridoxine 5'-phosphate is very low or 
essentially absent in plasma, considering a usual intake of vitamin B-6 (Lekem 2001). 
Pyridoxine hydrochloride (PN-HCl), a water soluble form, is used in commercial vitamin 
supplements and fortified foods. Vitamin B-6 is heat-stable in acid but heat-labile in alkaline 
or neutral solution; it is light-sensitive in solution (Leklem 1999). Muscle serves as a vitamin 
B-6 reservoir in which a majority of the vitamin is present as PLP bound to glycogen 
phosphorylase (Coburn et al. 1988). 
Absorption, Transport, and Metabolism 
The intestinal absorption of nonphosphorylated forms of vitamin B-6 (PL. PM, and 
PN), primarily occurs in the jejunum to a maj or extent by a nonsaturable passive process 
(Leklem 1999). The three phosphorylated B-6 vitamers (PLP, PMP, and PNP) are initially 
hydrolyzed by alkaline phosphatase in the intestinal mucosa to their respective 
dephosphorylated forms prior to absorption across the intestine (Bender 1992). When vitamin 
B-6 intake is high, some intact absorption of the phosphorylated forms does occur, but to a 
very limited extent (Lekem 2001). Pyridoxine glucoside, however, is absorbed less 
effectively than are PLP and PMP (Nakano and Gregory 1997). Pyridoxine glucoside needs 
to be deconjugated by a mucosal glucosidase, releasing metabolically active PN to be 
passively absorbed by tissues (Gregory et al. 1991; Nakano and Gregory 1995). 
The liver is the primary organ responsible for the metabolism of vitamin B-6 and 
supplies the active form, PLP, to the circulation and other tissue (Lekem 2001). The absorbed 
forms of vitamin B-6 which are taken up by the liver are primarily the nonphosphorylated 
forms. Pyridoxine, PL, and PM undergo phosphorylation by attaching a phosphate group at 
the 5' position by PN kinase, with zinc and ATP as cofactors (Leklem 1999). Alkaline 
phosphatase is responsible for the dephosphorylation of PNP, PLP, and PMP by removal of 
the 5'-phosphate group via hydrolysis (Bender 1992). Primarily the nonphosphorylated forms 
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are the vitamers that can be transported from one compartment to the other (Institute of 
Medicine 1998). The two phosphorylated forms, PNP and PMP, are converted to PLP by a 
flavin mononucleotide (FMN)-dependent PNP/PMP oxidase. The PL, resulting either from 
dephosphorylation or derived from dietary sources, can be irreversibly oxidized to 4-PA, the 
primary metabolic end-product, accounting for 40 to 60% of normal daily vitamin B-6 intake, 
by a flavin adenine dinucleotide (FAD)-requiring aldehyde oxidase or aFAD-dependent 
dehydrogenase (Bender 1992; Leklem 1991). The elimination of PL to 4-PA is of importance 
in the overall metabolism of vitamin B-6, serving as the primary route for the catabolism of 
B-6 vitamers (Leklem 2001). This irreversible reaction, the conversion of PL to 4-PA, plays 
the important role in metabolizing excess intake of vitamin B-6, which is excreted through 
the kidneys and thus prevents the accumulation of high concentrations of the reactive PLP 
form (Leklem 1988a; Leklem 1999). Urinary 4-PA is the main urinary metabolite of vitamin 
B-6, while there are small amounts of all six B-6 vitamers excreted in the urine (Leklem 
1988b). 
The metabolically active PLP that formed in the liver is either utilized directly or 
released into the circulation as a PLP-albumin complex (Bender 1992). In plasma, PLP is the 
primary form of vitamin B-6, predominantly as a PLP-albumin complex (Fonda et al. 1991). 
Plasma PLP in the form of a PLP-albumin complex protects it from hydrolysis by 
phosphatases and allows for the delivery of PLP to other tissues (Lekem 2001). 
Functions 
Pyridoxal 5'-phosphate, the primary coenzyme form of vitamin B-6, is required by 
over 100 enzymes including aminotransferases, decarboxylases, racemases and enzymes 
involved in side-chain elimination and replacement reactions. Of the over 100 enzymatic 
reactions in which PLP is involved, nearly half are aminotransferase-type reactions in which 
PLP reacts with ~-amino groups of lysine residues in proteins, forming a Schiff base with 
amino groups of amino acids so as to stabilize amino acid carbanions and hence to weaken 
bonds about the a-carbon of the substrate (Bender 1992). The cellular processes in which 
PLP is involved include amino acid metabolism, immune function, gluconeogenesis, niacin 
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formation, erythrocyte metabolism and function, lipid metabolism, neurotransmitter synthesis, 
and hormone modulation (Bender 1992; Leklem 2001). 
Gluconeogenesis 
Gluconeogenesis plays a key role in maintaining adequate concentrations of glucose 
during energy deficit (Leklem 2001). Pyridoxal phosphate is involved in gluconeogenesis via 
its coenzyme role in aminotransferase reactions and in the action of glycogen phosphorylase 
(Leklem 1999). In a rat study conducted by Angel (1980), results indicated decreased 
activities of hepatic alanine and aspartate aminotransferase in rats fed vitamin B-6 deficient 
diets for eight weeks. Glycogen phosphorylase, a key enzyme in the utilization of tissue 
glycogen reserve, catalyzes the sequential phosphorylysis of glycogen to release 
glucose-l-phospate, employing PLP as its coenzyme (Bender 1992). The phosphate group of 
PLP is the reactive moiety in the case of glycogen phosphorylase (Bender 1992). Animal 
studies have showed that glycogen phosphorylase activity of muscle increases as the intake 
of vitamin B-6 increases (Black et al. 1977). 
Niacin formation, lipid metabolism, and erythrocyte metabolism and function 
The direct conversion of tryptophan to niacin requires a PLP-dependent enzyme, 
kynureninase (Leklem 1999). Kynureninase catalyzes the conversion of 
3-hydroxyhynurenine to 3-hydroxyanthranilic acid in niacin formation from tryptophan. 
Leklem et al. (1975) investigated the effect of vitamin B-6 deficiency on the conversion of 
trypotophan to niacin. The investigators found that there was evidence that low vitamin B-6 
had a moderate negative effect on the conversion of tryptophan to niacin in women 
consuming a diet containing 0.2 mg of vitamin B-6 daily for 4 weeks. This was indicated by 
the significantly lower response to a 2 g tryptophan load test of the total urinary excretion of 
the two major niacin metabolites N-methyl-2-pyridone-5-carboxamide and 
N'-methylnicotinamide compared with women who consumed 1.8 mg of vitamin B-6 daily. 
The role vitamin B-6 plays in lipid metabolism remains controversial. Abe and 
Kishino (1982) reported that vitamin B-6-deficient rats fed high-protein diets developed fatty 
livers, whereas others did not (Abe and Kishino 1982; Leklem 1999). The findings from Abe 
and Kishino suggested that the resultant fatty liver in B-6-deficient rats was due to impaired 
lysosomal degradation of lipid (Abe and Kishino 1982). Nevertheless, Bender (1992) states 
that PLP has a clear role in lipid metabolism as the coenzyme for phosphatidylserine 
decarboxylation, leading to the formation of phosphatidylethanolamine, an intermediate in 
the synthesis of choline and phosphatidylcholine. Observations in a rat study conducted by 
Cunnane and coworkers (1984) suggested that both linoleic desaturation and 'y-linoleic acid 
elongation may be impaired when vitamin B-6 is deficient (Leklem 2001). 
Vitamin B-6 is essential in maintaining normal erythrocyte function and metabolism. 
The synthesis of heme, a component of hemoglobin, requires PLP. Pyridoxal phosphate 
functions as the coenzyme for b-aminolevulinic acid synthase involved in the conversion of 
succinyl CoA and glycine to b-aminolevulinic acid, the first and rate-limiting step in heme 
synthesis. Hemoglobin, a protein in erythrocyte, is essential to transport oxygen throughout 
the body. Apart from PLP as the coenzyme for aminotransferases in erythrocytes, vitamin 
B-6 via binding of both PLP and PL to hemoglobin plays a key role in maintaining a normal 
physiological state of the erythrocyte (Leklem 1999). Upon binding of PL to the a chain of 
hemoglobin, its oxygen binding affinity increased, whereas the binding of PLP to the ~ chain 
of the hemoglobin S or A lowers the oxygen binding affinity (Leklem 2001). 
Nervous system, immune function, and hormone modulation 
Pyridoxal phosphate acts as a coenzyme for decarboxylation reactions that lead to the 
synthesis of several neurotransmitters, including serotonin, taurine, dopamine, 
norepinephrine, histamine, and y-aminobutyric acid (Leklem 1999). Apart from the effect of 
vitamin B-6 on the direct conversion of tryptophan to niacin, there is another tryptophan 
pathway that requires aPLP-dependent enzyme, 5-hydroxytryptophan decarboxylase, 
converting 5-hydroxytryptophan to 5-hydroxytryptamine (Leklem 2001). 
A low intake of vitamin B-6 or decreased status is associated with impaired immune 
function in both animal (Robson and Schwarz 1975) and human studies (Meydani et al. 
1991). In humans, the percentage and total number of lymphocytes, mitogenic responses of 
peripheral blood lymphocytes to T and B-cell mitogens, and interleukin-2 production were 
significantly decreased during vitamin B-6 depeletion in healthy elderly adults (Meydani et al. 
1991). This impairment is reversible by vitamin B-6 repletion, suggesting that the indices of 
cell-mediated immunity may be mediated via one-carbon metabolism, particularly the 
activity of serine hydroxymethyltransferase (SHMT) and/or hormone modulation 
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(Trakatellis et a1.1992). The PLP-requiring enzyme, SHMT, is one of the key enzymes 
involved in one-carbon metabolism and the resultant reduced SHMT activity due to B-6 
inadequacy or deficiency might adversely alter one-carbon metabolism, leading to impaired 
changes in nucleic acid synthesis (Leklem 2001). 
Pyridoxal phosphate modulates steroid hormone receptors by binding to their receptor, 
thus inhibiting the binding of the steroid receptor to DNA, resulting in a decreased biological 
response for a given level of steroid. The Schiff base formed in the reactions of PLP with a 
lysine residue on the steroid receptor results in the inhibition of the binding of the steroid 
receptor complex to DNA (Leklem 2001). Pyridoxal phosphate reacts with receptors for 
estrogen, androgen, progesterone, and glucocorticoids in a reversible manner under 
conditions of physiological concentrations of PLP. This suggests that the vitamin B-6 status 
of an individual may have implications for diseases affected by steroid hormones, such as 
prostate and breast cancers (Leklem 2001). 
Amino acid metabolism 
Pyridoxal phosphate is involved in amino acid metabolism via reactions with the 
a-amino group of the substrate. The PLP-requiring reactions include (Leklem 2001): (1) 
decarboxylation of amino acids to yield amines involving the a carbon of PLP, which are 
hormones or neurotransmitters, such as serotonin, y-aminobutyric acid, and noradrenaline 
(and hence adrenaline); (2) transamination of amino acids to yield their keto-acids (oxo-acids) 
involving the a carbon of PLP, which are then oxidized as metabolic fuels; (3) reactions 
involving the side-chains of amino acids, including cystathionine (3-synthase and 
cystathionase in replacement reactions occurring at the (3 and 'y carbons of PLP, respectively, 
and kynureninase in cleavage reactions occurring at 'y carbon of PLP; and (4) decarboxlation 
of phosphatidylserine to phosphatidyl-ethanolamine in phospholipid synthesis occurring at 
the a carbon of PLP. 
Food Sources and Bioavailability 
Vitamin B-6, as an essential nutrient, is not synthesized in the body but obtained from 
dietary sources. The richest sources of vitamin B-6 include chicken, fish, beef liver and other 
organ meats, pork, eggs, and yeast, providing more than 0.4 mg/ 1 OOg serving. Other good 
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sources include soybeans, oats, peanuts, walnuts, unmilled rice, and whole wheat products; 
vegetables and cereals (not corn) are intermediate sources. Dairy products, red meat, and fruit 
(except bananas), are relatively poor sources of vitamin B-6 (NRC 1989). The greatest 
contribution to vitamin B-6 intake of the U.S. adult population is from fortified, ready-to-eat 
cereals, followed by mixed foods with meat, fish, or poultry as the main ingredient, white 
potatoes and other starchy vegetables, and noncitrus fruits (Institute of Medicine 1998}. 
Nutrient bioavailability from a given food is defined as the amount of a nutrient that 
is both absorbed and available to cells. When the vitamin is described as "available", it is 
understood that the vitamin may not be needed by the cell and simply excreted or 
metabolized to a nonutilizable form, such as urinary 4-PA excretion in the case of vitamin 
B-6 (Leklem 2001).Vitamin B-6 bioavailability is defined as the proportion of dietary B-6 
vitamers that are absorbed and utilized in B-6 metabolism. The evaluation of the 
bioavailability of vitamin B-6 depends on our understanding of the various forms and the 
quantities of these B-6 vitamers in foods. As aforementioned, the major forms in animal 
foods are PLP and PMP, whereas PN and PNP, sometimes in the form of a glucoside or PNG, 
are primary forms of the vitamin in plant-derived foods. The bioavailability of vitamin B-6 in 
a mixed diet is considered about 75 percent, with approximately 8 percent of the total 
contributed by PNG Pyridoxine glucoside is estimated at 50 to 58 percent of the 
bioavailability of PN as based on dose studies using deuterium-labeled PNG. The six 
interconvertable nonglucoside forms of vitamers (PN, PL, PM, PNP, PLP, and PMP) show 
greater than 75 percent bioavailability (Gregory 1997). Pyridoxine-l3-D-glucoside (PNG), a 
major naturally occurring form of vitamin B-6 in plant-derived food, is a glycosylated form 
of vitamin B-6 that is poorly digested and virtually absent in foods of animal origin, but 
identified to constitute 5-80% of the total vitamin B-6 in plant foods (Gregory and Sartain 
1991). 
Kabir et al. (1983) conducted controlled-feeding studies in which the relative 
bioavailability of vitamin B-6 was examined from tuna, whole wheat bread, and peanut 
butter in eight men with 1.6 mg vitamin B-6 intake daily. Their findings indicate that the 
percentage of PNG in these foods was inversely correlated with vitamin B-6 bioavailability 
as based on urinary vitamin B-6 and 4-PA. Leklem et al. (2001) observed an inverse 
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relationship between vitamin B-6 bioavailability and the glycosylated vitamin B-6 content of 
six foods, indicating that the glycosylated vitamin B-6 content of foods appears to 
significantly affect bioavailability. The lower vitamin B-6 bioavailability in plant foods 
compared with animal products is possibly partially due to the inadequate cleavage of the 
glucoside moiety of pyridoxine from PNG. Approximately half of the dietary vitamin B-6 
intake of Americans is from plant sources (Kant and Block 1990). Thus, studies addressing 
PNG bioavailability in vivo have drawn more and more attention. Studies with various 
designs have shown us the diverse aspects of PNG bioavailability. 
To determine whether the bioavailability of vitamin B-6 is lower in diets in which 
vitamin B-6 is mostly from plant sources, comparisons between free-living vegetarian and 
nonvegetarian populations with self-selected diets showed that diet type (vegetarian or 
nonvegetarian) did not result in significantly different daily vitamin B-6 intakes. There were 
no significant differences in plasma or erythrocyte status indicators (Shultz and Leklem 1988; 
Lowik 1990). To investigate the extent to which PNG bioavailability affects vitamin B-6 
status, Hansen et al. (1996b) conducted a controlled study in which young women were fed. 
either low (9%) or moderately high (27%) percentages of glycosylated vitamin B-6 diets. The 
higher intake of PNG caused a decrease in vitamin B-6 status as indicated by plasma and 
erythrocyte status indicators. These findings indicate that, in a controlled study, the 
bioavailability of PNG is incomplete and of sufficient magnitude to affect nutritional status 
(Hansen et al. 1996b; Gregory 1998). To examine whether the intact glucoside has 
antagonistic effects on various aspects of vitamin B-6 metabolism, in vivo studies with rats 
were conducted (Gilbert and Gregory 1992; Nakano and Gregory 1995). Findings indicated 
that, as reflected by increased urinary excretion and a small accumulation of hepatic PNG, 
the consumption of the PNG in the presence of PN or alone caused in vivo alteration of 
vitamin B-6 metabolism (Gregory 1998). The adverse effect of PNG on the utilization of 
other forms of the vitamin complicates the assessment of the overall bioavailability of total 
dietary vitamin B-6. Pyridoxine-l3-D-glucosides have great nutritional significance due to 
their widespread natural occurrence in plants, their role as a partially bioavailable form of 
vitamin B-6 in human nutrition, and the weak antagonism of the utilization of 
nonglycosylated forms of the vitamin in mammals (Gregory 1998). 
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Apart from the effect of PNG content on vitamin B-6 bioavailability, fiber intake 
appears to be a contributor to bioavailability (Lindberg et al. 1983; Hansen 1996b). Lindberg 
et al. (1983) have shown that the addition of 6.4 g dietary fiber daily as 15 g of wheat bran to 
the diet decreased vitamin B-6 bioavailability modestly by up to 17%based on urinary 4-PA 
and total vitamin B-6. Hansen et al. (1996b) reported that the resultant reduced vitamin B-6 
bioavailability of diets that are high in PNG are also high in dietary fiber. This may have an 
important effect on vitamin B-6 status for people with marginal vitamin B-6 intakes or those 
consuming diets in which most of the vitamin B-6 intake is from plant foods. 
Status Assessment 
There are three ways of assessing vitamin B-6 status: direct methods, indirect 
methods and dietary intake. Direct methods measure the concentration of the B-6 vitamers or 
the metabolite 4-PA in various biological fluids and erythrocytes. These include 
measurements of plasma PLP, PL, plasma total vitamin B-6, erythrocyte vitamin B-6 
metabolites, urinary 4-PA and urinary total vitamin B-6. The indirect or functional method 
assesses vitamin B-6 status based on measurement of products in metabolic pathways or 
enzyme activities that require PLP as a conenzyme. These include measurement of urinary 
metabolite excretion in response to an oral methionine or typtophan load and measurement of 
the PLP-dependent enzyme erythrocyte alanine or aspartate aminotransferase activities with 
and without stimulation by the coenzyme PLP (Leklem 1999; Ink and Henderson 1984). 
Most investigators suggest using several measures, including both direct and indirect, in 
addition to an evaluation of dietary intake of both vitamin B-6 and protein (Leklem 1999; 
Hansen et al. 1997). Protein intake should be taken into consideration because it has been 
observed that greater intake is associated with reduced plasma PLP concentration and urinary 
4-PA excretion (Miller et al. 1985; Hansen et al. 1996a). Table 2.1 (p.12) lists suggested 
values for different vitamin B-6 measures indicating adequate status (Leklem 1990). 
Direct methods 
Plasma vitamin B-6 and its metabolites: Currently, the quantification of fasting 
plasma PLP concentration is the most frequently used direct method to assess vitamin B-6 
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Table 2.1. Indices for evaluating vitamin B-6 status and suggested values for adequate status 
in adults (Leklem 1990). 
Index 
Suggested value for 
adequate status 
Direct 
Blood 
Plasma pyridoxal 5'-phosphate 
Plasma pyridoxal 
Plasma total vitamin B-6 
Erythrocyte pyridoxal 5'-phosphate 
Urine 
4-Pyridoxic acid 
Total vitamin B-6 
Indirect 
Blood 
Urine 
Erythrocyte alanine aminotransferase 
index 
Erythrocyte aspartate aminotransferase 
index 
2-g tryptophan load; xanthurenic acid 
excretion 
3 -g methionine load; cystathionine 
Dietary Intake 
Vitamin B-6 intake 
Vitamin B-6/protein ratio 
Other 
Electroencephalogram patterns 
> 3 0 nmol/L 
allot Available 
> 40 nmol/L 
Not Available 
> 3.0 µmol/d 
> 0.5 µmol/d 
< 1.25 
< 1.80 
< 65 µmol/d 
< 350 µmol/d 
> 1.2-1.5 mg/d 
> 0.020 mg/g 
allot Available 
allot Available, adequate value has not been determined 
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status. Plasma PLP, the primary circulating form of vitamin B-6, comprises approximately 
50% to 75% of the total vitamin B-6 in plasma (Leklem 1999). Based on rat studies, plasma 
PLP concentration correlates well with tissue vitamin B-6, which suggests that it is reflective 
of tissue stores, thus considered an appropriate index of vitamin B-6 status (Lumeng et al. 
1978). Human metabolic studies have shown that when intake is in the range of 0.5 to 1.0 
mg/day, plasma PLP concentration changes in response to change in dietary vitamin B-6 
intake, taking about 10 days to reach a new steady state (Lui et al. 1985; Leklem 1999). 
Plasma PLP concentration increases with an increase in dietary vitamin B-6 intake and its 
concentration falls in response to increased protein intake (Leklem 1999). A cutoff for PLP in 
plasma of 20 nM was selected by the Dietary Reference Intake (DRI) committee as the 
basis for the estimated average requirement (EAR) for vitamin B-6, in the absence of 
evidence linking a particular concentration to favorable or unfavorable health outcomes 
(Institute of Medicine 1998). However, other investigators suggested a higher concentration 
of 30 nM as the lower end of normal for plasma PLP based on human metabolic studies 
(Leklem 1990; Hansen et al. 1996a). The use of plasma PLP concentration, a single 
measurement, is limited because several factors influence it. Asthma, coronary heart disease, 
or pregnancy may result in an abnormally low concentration of plasma PLP (Leklem 1999). 
Thus, the use of several indicators in conjunction with each other has been suggested for 
evaluating vitamin B-6 status (Leklem and Robert 1981). 
Plasma PL, comprising about 8% to 30% of the total plasma vitamin B-6, is the 
second most abundant form in plasma. Its measurement may be more relevant than that of 
PLP since it is a form that crosses all membranes and enters the cell (Leklem 1999). However, 
analysis is technically difficult because its concentration indicating adequate status has not 
been established. Thus, plasma PL is only recommended as one of the direct vitamin B-6 
status measures (Leklem 1999). Additional research is necessary to determine the extent to 
which plasma PL is a valid vitamin B-6 status indicator. 
Erythrocyte PLP: Erythrocyte PLP concentration has been suggested as an additional 
index to assess vitamin B-6 status. However, it may be unrepresentative of other body tissues 
due to particular characteristics of the erythrocyte, such as the tight binding ability of 
hemoglobin to both PLP and PL, together with the relatively long life ( 120 d) of the 
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erythrocyte, complicating the usefulness of erythrocyte PLP concentration as an indicator of 
vitamin B-6 status (Leklem 1999). Erythrocyte PLP concentration increases to a greater 
extent than plasma PLP when subjects consume large doses of vitamin B-6 (Bhagavan et al. 
1975). The use of blood total vitamin B-6 concentration and the individual concentration of 
specific B-6 vitamers, such as plasma PL and erythrocyte PLP as status indicators, is limited 
due to the fact that they tend to fluctuate considerably (Contractor and Shane 1968). 
Urinary 4-PA excretion: Urinary 4-PA excretion and urinary total vitamin B-6 (the 
sum of the nonphosphorylated and phosphorylated forms) have been used extensively to 
evaluate vitamin B-6 requirements (Institute of Medicine 1998). However, the urinary levels 
of vitamin B-6 are not useful long-term status indicators because they fluctuate considerably, 
reflecting recent vitamin B-6 intakes. Urinary 4-PA, the metabolic end-product of vitamin 
B-6, is considered as a short-term status indicator and represents 40% to 60% of the daily 
vitamin B-6 intake under normal conditions (Leklem 1999). Its excretion changes rapidly in 
response to change in vitamin B-6 intake over a 1- to 4-day period and the fluctuation in 
urinary 4-PA parallel that of plasma PLP in response to change in vitamin B-6 intake. Thus, 
urinary 4-PA level reflects recent dietary intake (Leklem 1999). A value of greater than 
3 µmol/day has been suggested as indicative of adequate status (Leklem 1990). To measure 
urinary vitamin B-6, several 24-h urine collections during 1 to 3 weeks are required (Leklem 
1999). Several dietary and physiologic factors have been shown to affect urinary 
measurements. For instance, an increase in protein intake results in a decrease in urinary 
4-PA excretion. Also, use of vitamin B-6 antagonists, such as the drugs isoniazid, 
penicillamine, or cycloserine, and injection of oral contraceptives appear to affect this 
measurement (Leklem 1999). Urinary 4-PA is a valuable vitamin B-6 status indicator if 
dietary vitamin B-6 intake is controlled. 
Indirect methods 
Trypotophan Ioad test: A trypotophan load test, based on the requirement for PLP in 
the major catabolic pathway of trypotophan, has been the most widely used indirect indicator 
of vitamin B-6 status (Leklem 1999). Greenberg et al. (1949) conducted a vitamin B-6 
restrictive diet study in man, which is known as the first investigation to observe an increased 
excretion of xanthurenic acid, a colored compound, after a load of trypotophan. In the 
15 
trypotophan metabolic pathway, under normal conditions, the enzyme tryptophan oxygenase 
is the rate limiting step. However, when vitamin B-6 deficiency occurs, the activity of the 
PLP-dependent enzyme kynureninase falls below that of tryptophan oxygenase and results in 
the accumulation of intermediates and an increased urinary excretion of kynurenic and 
xanthurenic acid (Holman 1995). For this measure, urinary xanthurenic acid excretion is 
measured after a 2-g oral test load of L-trypotophan (Leklem 1999). A 24-h urinary excretion 
of less than 65 µmol post-load xanthurenic acid is considered indicative of normal vitamin 
B-6 status (Leklem 1999). In subjects with adequate vitamin B-6 status, a urinary excretion 
of xanthurenic acid usually ranges from 3 o to 4o µmol/day in response to the 2-g of 
tryptophan (Leklem 1999). The reliability of the tryptophan load test has been questioned due 
to an adverse effect on trypotophan metabolism by several factors other than vitamin B-6 
status. These factors include protein intake, exercise, lean body mass, individual variation, 
loading dose of tryptophan, use of estrogen and oral contraceptives, and pregnancy (Bender 
1992; Leklem 1999). Essentially, tryptophan oxygenase activity varies with several factors, 
such as substrate availability, hormonal induction, feedback by NAD and NADP, and 
availability of the heme cofactors (Holman 1995). In addition, diseases such as Hodgkin's 
lymphoma, rheumatoid arthritis, schizophrenia, porphyria, renal tuberculosis, and aplastic 
anemia have been found to affect the tryptophan load test independently of vitamin B-6 
status (Holman 1995). Despite all of these disadvantages of the tryptophan load test, it is 
regarded as a valid indicator of vitamin B-6 status when conditions that adversely affect test 
outcome are absent (Leklem 1999). 
Methionine load test: The methionine load test, like the tryptophan load test, 
primarily reflects hepatic vitamin B-6 status and has also been used as an indirect measure of 
vitamin B-6 status, based on the four PLP-dependent steps in methionine metabolism 
(Leklem 1999). The step in the methionine pathway that is catalyzed by cystathionase, in 
which cystathionine is cleaved to form homoserine and cysteine, appears to be especially 
sensitive to vitamin B-6 deficiency. This is reflected by elevated urine excretions of the 
metabolites cystathinonine and cysteine sulfonic acid following a methionine load (Leklem 
1999). cystathionase activity falls in vitamin B-6 deficiency, as evidenced by an increase in 
the tissue content of the inactive apo-enzyme (Bender 1992). Linkswiler (1981) indicated 
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that there is an increase in the urinary excretion of cystathionine, both after a loading dose of 
methionine and under basal conditions, and the metabolism does not appear to be subject to 
the same artifacts as does the tryptophan load test (Bender 1992). Thus, the methionine load 
test is considered a useful test of vitamin B-6 status and good agreement between impairment 
of methionine metabolism and other indices of vitamin B-6 status has been established 
(Bender 1992). However, because the methionine load test has been used in a limited number 
of studies, the cutoff value for urinary cystathionine of less than 350 µmol/day is based on 
three studies and no definitive values are available for cysteine sulfonic acid (Leklem 1999). 
Increase in plasma homocysteine concentration after a methionine load: More 
recently, an increase in plasma homocysteine after a methionine load has been observed in 
vitamin B-6 deficiency, providing a potential indirect or functional indicator of vitamin B-6 
status (Leklem 1999). There are two PLP-dependent enzymes involved in homocysteine 
catabolism via transsulfuration to cysteine. Homocysteine can also be remethylated to 
methionine via folate and vitamin B-12-dependent enzyme (Institute of Medicine 1998). 
Thus, vitamin B-6, folate, and to a lesser extent vitamin B-12 intakes, are considered to be 
factors affecting plasma homocysteine concentration (Selhub et al. 1993). With the increased 
interest in the relationship between plasma homocysteine and risk of coronary heart disease, 
there have been several studies in which the effect of vitamin B-6 on plasma homcysteine has 
been examined (van den Berg et al. 1994; Ubbink et al. 1994). van den Berg et al. (1994) 
found that simple and inexpensive therapy with vitamin B-6 plus folic acid for at least six 
weeks normalized homocysteine metabolism in 72 patients (aged < 50 y) with cardiovascular 
disease and mild hyperhomocysteinemia (defined as an increase in the plasma homocysteine 
concentration after methionine loading to greater than 97.5 percentile of age-matched control 
subjects but less than 200 µmol/L; van den Berg et al. 1994). A study conducted by Miller et 
al. (1994) examined responses to methionine loading in vitamin B-6 deficient vs. folate 
deficient rats. They reported that rats fed vitamin B-6 deficient diets for 4 weeks and given a 
gastric gavage of methionine (100 mg/kg body wt) exhibited a peak post-methionine load 
increase (> 300 µmol/L) in plasma homocysteine concentration. In contrast, folate-deficient 
rats exhibited no significant changes in plasma homocysteine concentration after the load. 
The investigators explained this phenomenon by the observed increase in hepatic 
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S-adenosylmethionine (SAM) concentration because of the load. They pointed out that when 
vitamin B-6 is deficient under conditions of a methionine load, significant increases in the 
syntheses of both SAM and homocysteine occur. The homocysteinemia was resulted from 
the following three factors: vitamin B-6 deficiency or enzyme defect led to the reduction of 
transsulfuration; the increased homocysteine because of the methionine load must be 
metabolized; and increased SAM inhibits the methylenetetrahydrofolate reductase, thus 
impairs homocysteine remethylation. The impaired homocysteine remethylation in 
conjunction with the impaired homocysteine catabolism due to vitamin B-6 deficiency and 
the increased synthesis of homocysteine due to the methionine load, led to the large elevation 
of homocysteine in the blood. However, when folate deficiency occurs under conditions of a 
methionine load, there are again increases in the syntheses of both SAM and homocysteine. 
Although the increased homocysteine synthesis would be expected to raise plasma 
homocysteine concentrations, the raise in tissue SAM will activate cystathionine ~3-synthase, 
the enzyme that initiates homocysteine catabolism. The increased cystathionine ~3-synthase 
induces an acceleration of homocysteine catabolism, which compensates for the increased 
synthesis of homocysteine due to the load and thus no change in blood homocysteine was 
observed. The observed increased plasma homocysteine concentration after a methionine 
load in the face of vitamin B-6 deficiency, therefore, provides a potential indirect indicator of 
vitamin B-6 status. 
Erythrocyte aspartate aminotransferase and alanine aminotransferase: Measurement 
of erythrocyte aspartate aminotransferase and erythrocyte alanine aminotransferase activity 
with and without PLP stimulation has been frequently used to evaluate long-term vitamin B-6 
status due to the life span of erythrocytes (Institute of Medicine 1998; Leklem 1999). Two 
measurements are used in the test: the unstimulated, or basal enzyme activity as removed 
from the subject, and the stimulated enzyme activity after the in vitro addition of excess PLP 
(Leklem 1999). Two additional values are derived from these data. One is the stimulation 
index as calculated by the ratio of stimulated activity to unstimulated activity (Leklem 1999). 
The other is the percent stimulation which is calculated from the following formula 
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(Leklem 1999): Percent stimulation = 
~SA—UA~x100 
UA 
where SA presents stimulated activity and UA presents unstimulated activity (Leklem 1999). 
Human studies provide evidence that activity of these two enzymes is decreased in 
individuals whose vitamin B-6 reserves have been depleted, whereas activity is increased 
after the in vitro addition of excess PLP (Leklem 1999). The usefulness of aminotransferase 
activity measures as an index of a specific vitamin B-6 intake level is limited because the 
concentration of these enzymes fluctuates in the blood as a result of tissue damage and 
turnover (Holman 1995). In individuals with apparently adequate vitamin B-6 status, there is 
considerable interindividual variation in the erythrocyte aminotransferase activity with or 
without stimulation by added PLP, shown to vary by as much as 25%and 50% for 
erythrocyte alanine aminotransferase and erythrocyte aspartate aminotransferase, respectively 
(Leklem 1990). Moreover, the temporal relationship between the measurement of enzyme 
activity and vitamin B-6 intake is poorly understood (Leklem 1999). No long-term studies 
(more than six wks) have measured aminotransferase activities after different levels of 
vitamin B-6 were fed (Leklem 1999). In addition, the existence of three phenotypes of 
erythrocyte alanine aminotransferase has been documented and their activity differs (Holman 
1995; Leklem 1999). Furthermore, the affinity of the albumin to which PLP is bound 
partially influences the saturation of plasma aminotransferases (Holman 1995). There are 
additional limitations of this method; for example, abnormalities in erythrocyte 
aminotransferase arise in liver disease (Holman 1995) or in riboflavin deficiency (Leklem 
1999). Also, as influenced by the duration of erythrocyte life span in the circulation (~ 120 d), 
erythrocyte aminotransferase activation is not as rapidly responsive to acute vitamin B-6 
depletion as other indices (Holman 1995). A standardized approach to reporting results from 
this assay is needed due to a lack of uniform method in reporting data and comparing results 
among studies. 
Serine hydroxymethyltransferase activity: Serine hydroxymethyltransferase (SHMT), 
a PLP-dependent enzyme, has received attention recently for its importance in homocysteine 
remethylation and one-carbon metabolism (Davis 2005). Serine hydroxymethyltransferase 
catalyzes the transfer of the three-carbon of serine to tetrahydrofolate to produce 
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5,10-methylenetetrahydrofolate, which is reduced by methylenetetrahydrofolate reductase to 
produce 5-methyltetrahydrofolate (Davis 2005). Five-methyltetrahydrofolate is involved in 
remethylation of homocysteine by methionine synthase. Thus, if vitamin B-6 deficiency 
occurs, it reduces SHMT activity that might result in the impairment of homocysteine 
remethylation .The sensitivity of SHMT activity and homocysteine metabolism to vitamin 
B-6 status in animal studies (Martinez et al. 2000) suggests that impaired homocysteine 
remethylation might also occur in vitamin B-6 deficiency in humans (Davis 2005). Human 
study in healthy, nonsmoking 20-30-y-old men and nonpregnant women (Davis 2005) 
showed that dietary vitamin B-6 restriction significantly reduced basal and PLP-stimulated 
lymphocyte SHMT activities in vitro. Further investigation is needed to evaluate the 
usefulness of SHMT activity as a measure of vitamin B-6 status. 
Dietary intake 
It is not advisable using dietary intake of vitamin B-6 alone (or the vitamin 
B-6-to-protein ratio implied) to evaluate status due to the difficulty in obtaining accurate 
dietary assessment data and lack of complete data for the vitamin B-6 content of foods 
(Leklem 2001). Several status indicators, including both direct and indirect measures, in 
addition to an evaluation of both vitamin B-6 and protein intake are necessary to properly 
assess vitamin B-6 status (Leklem 1990). 
Requirement 
There are several factors that have been identified that may affect the determination 
of vitamin B-6 requirement. Dietary factors affecting bioavailability may affect the 
requirement, such as forms of vitamin B-6 in foods (animal/plant foods). Defects in delivery 
to tissues and cells, such as impaired gastrointestinal absorption and impaired transport, may 
play a role affecting vitamin B-6 metabolism and thus requirement. Increased catabolism, 
growth, gender differences, aging, and physical activity levels are recognized 
physiological/biochemical factors that influence vitamin B-6 requirement. Nutrient-nutrient 
interactions such as vitamin B-6 interactions with riboflavin or carbohydrate; genetic factors 
such as defects in apoenzymes requiring PLP and altered concentrations of apoenzymes 
requiring PLP are also associated with vitamin B-6 requirement. Additional factors may 
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affect requirement such as drug interactions, as indicated by people taking isoniazid who 
have reduced plasma PLP concentrations (Weir et al. 1991), by women using high-dose oral 
contraceptive agents who have reduced vitamin B-6 status (Shane and Contractor 1975), and 
by alcoholics consuming alcohol who have a reduced plasma PLP concentration that is 
distinct from that which is caused by liver disease or poor diet (Institute of Medicine 1998). 
Among these factors, the direct relationship between protein intake and the need for 
vitamin B-6 was employed to set a requirement for vitamin B-6 intake in 1989. A value of 
0.016 mg of vitamin B-6 per gram of protein was set as the basis for adults to meet the 1989 
RDA value for vitamin B-6 (Leklem 1999). Human feeding studies have provided 
information for setting vitamin B-6 RDAs for individuals of each gender at different stages 
of life. Hansen and coworkers (2001) assessed the vitamin B-6 requirements of young 
women receiving 12 g protein/kg body weight fora 7-d period of 1.0 mg B-6/d, followed by 
three successive 14-d experimental periods of 1.5, 2.1, and 2.7 mg B-6/d. Their findings 
indicated that dietary vitamin B-6-to-protein ratio was significantly correlated with urinary 
4-PA and total vitamin B-6, plasma PLP, total vitamin B-6 and 4-PA, and erythrocyte PLP. 
They have shown higher vitamin B-6-to-protein ratios of 0.018-0.020 mg/g protein than the 
recommended ratio in 1989 (0.016) are required to achieve adequacy. This study suggests 
that the current vitamin B-6 RDA may not be adequate. The most recent RDA for vitamin 
B-6 is not expressed in terms of protein intake, although the relationship was considered in 
setting the RDA in 1989. Considering that plasma PLP is reflective of tissue stores of vitamin 
B-6, the current RDA for vitamin B-6 is based on a plasma PLP concentration of at least 
20 nM by the DRI committee (Institute of Medicine 1998). 
Methods that have been used to assess the vitamin B-6 requirement include metabolic 
balance studies, depletion/repletion studies, functional tests such as the tryptophan load test 
and methionine load test, dietary intake of populations, and metabolic turnover (measurement 
of pools) (Leklem 2001). Although the latter method above received little attention, it 
provides the best information upon which to base requirements (Leklem 2001). There are 
several limitations of methods being used to estimate the vitamin B-6 requirement. First, one 
of the assumptions for setting the RDA is that the intake data are from a healthy population 
(Leklem 2001). However, this is not always the case. Often this health information is not 
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adequately documented in large population-based studies (Leklem 2001). Moreover, the 
nutrient data bases being used to interpret vitamin B-6 intake are not complete. A significant 
number of foods do not have vitamin B-6 values, resulting in an underestimation of vitamin 
B-6 intake (Leklem 2001). In addition, the comparison made from the data across studies is 
not consistent due to the fact that various levels of protein were utilized. Leklem (2001) 
suggests that well designed studies with several indices of vitamin B-6 status considered 
would provide a better understanding of overall metabolism of vitamin B-6. Vitamin B-6 
status is best assessed using a direct measure, ashort-term indicator, an indirect measure, and 
appropriate dietary information in a healthy population (Leklem 1990). 
The 1989 RDA for vitamin B-6 was 1.6 and 2.0 mg/d for women and men, 
respectively, ages 19-50 y (Leklem 1999; NRC 1989). However, in 1998 more than 50% of 
the U.S. population consumed less than the 1989 RDA (Leklem 1999). More recently, the 
vitamin B-6 EAR and RDA for women and men ages 19-50 y was decreased to 1.1 and 1.3 
mg/d, respectively. Considering plasma PLP is reflective of body stores of vitamin B-6, a 
plasma PLP value of 20 nM was used as the primary criterion to estimate the RDA for 
vitamin B-6. This was done in the absence of evidence linking a particular concentration to 
favorable or unfavorable health outcomes (Institute of Medicine 1998). Plasma PLP 
concentration was chosen as the standard for assessing adequate status because it appears to 
be reflective of the tissue stores of the vitamin (Liu et al. 1985). A coefficient of variation 
(CV) of 10% is assumed for vitamin B-6 because information is not available on the standard 
deviation of the requirement (Institute of Medicine 1998). The RDA for vitamin B-6 is 
defined as equal to the EAR plus twice the CV to cover the needs of 97 to 98 percent of 
individuals in the group (Institute of Medicine 1998). That is to say, the RDA for vitamin B-6 
has been estimated as being 120 percent of the EAR, which is 1.1 mg B-6/d (NRC 1989). 
The current vitamin B-6 RDAs are based on metabolic studies, vitamin B-6 intake data, and 
protein intake of populations (Leklem 1999; Institute of Medicine 1998). A mean PLP 
concentration close to 20 nM was achieved in past studies (Institute of Medicine 1998) in 
subjects with an intake of 1.0 mg of vitamin B-6 (1.25 mg of food B-6). In most studies, PN 
is used and its bioavailability is estimated as 95%compared to 75%for food B-6 (Institute of 
Medicine 1998). Thus, for the EAR determination, a conversion factor of 1.27 (95=75) has 
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been added to dietary B-6 equivalents in the following formula (Institute of Medicine 1998): 
mg of dietary B-6 equivalents provided = [mg of food B-6 + (1.27Xmg of synthetic B-6)]. 
The RDAs are set to 1.9 mg and 2.0 mg vitamin B-6 per day to meet the additional 
requirement in pregnancy and lactation, respectively (Institute of Medicine 1998). 
Rationale 
Our understanding of overall bioavailability of vitamin B-6 in human diets is still 
incomplete, although several factors affecting vitamin B-6 bioavailability have been 
identified. Recognition of the health effects of soy, such as a health claim approved by the 
FDA in 1999 that soy protein reduces the risk of coronary heart disease by lowering blood 
cholesterol, has led to an increase in soyfoods consumption (Messina et al. 2002). However, 
there is limited information about the forms of vitamin B-6 in commercially available 
soyfoods and soy protein products have not been fortified with vitamin B-6. The PNG 
content in cooked whole soybeans was estimated as 57% of the total vitamin B-6 and the 
PNG content in soy flour was found to be 67% of the total vitamin B-6 (Gregory and Sartain 
1991). Compared with tuna, the bioavailability of vitamin B-6 in soybeans was estimated at 
41 %. Apart from the effect of PNG content on vitamin B-6 status, there are some other 
factors that may affect the bioavailability of vitamin B-6 in soy. In an animal study (Lu and 
Huang 1997), with the same intake of vitamin B-6, rats fed soy protein isolate excreted twice 
the amount of urinary xanthurenic acid compared to rats fed casein along with a vitamin 
B-6-deficient diet for 5 weeks and given a tryptophan load. The reduced vitamin B-6 status in 
the rats fed soy protein was also reflected in decreased erythrocyte aminotransferase activity. 
These results suggest that, apart from the effect of PNG content on vitamin B-6 status, there 
might be an additional adverse effect on vitamin B-6 status when replacing milk protein with 
soy protein. 
Middle aged women (ages 35-55 y) were studied because women in this age group 
frequently have marginal intakes of vitamin B-6 (Institute of Medicine 1998) and many drink 
soymilk for its purported beneficial health effect on menopausal symptoms, especially 
alleviating hot flushes and night sweats (Kronenberg and Fugh-Berman 2002). There has 
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been limited information regarding the PNG content of soymilk. The effect of substituting 
soy products for animal products on vitamin B-6 status has not been investigated. 
Objectives 
This study investigated the effect of substituting soymilk for cow's milk on vitamin 
B-6 status in middle aged women (aged 36-52 y; n=16). The specific aims of this research 
were to determine the effects of substituting soymilk for cow's milk on: 1) vitamin B-6 
metabolite concentrations of plasma PLP, 4-PA and urinary 4-PA; 2) homocysteine 
concentration in fasting blood and after a methionine load; we also determined the 
differences in these effects on vitamin B-6 status between soymilk drinkers and milk drinkers. 
We hypothesized that women substituting soymilk for cow's milk will have decreased 
concentrations of plasma PLP, 4-PA, and urinary 4-PA, as well as elevated concentrations of 
plasma homocysteine after a methionine load. 
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CHAPTER 3. MATERIALS AND METHODS 
Methods 
Subject selection 
Eighteen middle-aged women (aged 36-52 y) were recruited by advertisements in 
newspapers and announcements posted and circulated throughout the community. Volunteers 
were interviewed by study personnel, and the study was fully explained, including the risks 
and benefits to the subject. The volunteers' suitability for the study was initially determined 
based on the health history, food likes and dislikes, and physical activity level. Potential 
subjects were additionally screened using a fasting blood draw for evaluation of vitamin B-6 
status and clinical chemistry evaluation. Subjects kept a 3 -d diet record prior to the study to 
estimate usual nutrient intake. Nutrient composition of the 3-d diet record was analyzed by 
Food Processor (Version 8.5.0, ESHA Research, Salem, Oregon). Prior to starting the study, 
subjects consumed (mean ~ SD) 2055 ~ 625 kcal/d with a mean (~ SD) vitamin B-6 intake of 
1.83 ~ 0.73 mg/d and a mean (~ SD) vitamin B-6-to-protein, ratio of 0.0241 ~ 0.0094 mg/g. 
Subject inclusion criteria were as follows: [1] no illness or medical condition 
requiring a physician's supervision; [2] no history of gastrointestinal disorders which could 
influence digestion or absorption; [3] no history of heart, liver, or kidney disease, diabetes, 
alcoholism, cancer, hypertension, epilepsy or related convulsive disease, or other metabolic 
diseases; [4] for premenopausal women, a regular menstrual cycle length of 26 to 32 d 
(pregnant and lactating women were excluded from participation); [5] no hormonal therapy 
(e.g., oral contraceptives, estrogen, androgen, progesterone, or glucocorticoids) or other 
drugs (e.g., isoniazid, penicillamine, and others), which would influence vitamin B-6 
metabolism; [6] no use of vitamin or other nutritional supplements for at least 6 wk prior to 
the beginning of the study; [7] no food allergies; [8] alcohol consumption less than 56.7 g 
pure ethanol/wk; [9] no weight change greater than 4 kg within the last year; [ 10] no 
participation in strenuous activity such as long-distance running or bicycling; [ 11 ] normal 
blood chemistry evaluation, including liver and thyroid function, glucose, protein, creatinine, 
electrolytes, triglycerides, and cholesterol; [ 12] normal vitamin B-6 status. 
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The characteristics of the subjects are listed in Table 3.1 (p. 26). The Institutional 
Review Board of Iowa State University reviewed and approved the screening and 
experimental procedures, and informed consent was obtained from each subject. Subjects 
were instructed to maintain their usual physical activity level throughout the study. Eighteen 
subjects began the study, one subject dropped out during the washout period, and one 
subject's data were eliminated because of analytical difficulties. Sixteen people were 
included in our final data analyses. As shown, subjects' initial weight (mean ~ SD) was 80.8 
~ 20.8 kg and final weight was 80.0 ~ 20.7 kg. Their age (mean ~ SD) was 41.8 ~ 4.9, with 
14 Caucasians, 1 African (Zambian), and 1 Asian (Malaysian). 
Experimental design 
The study employed a crossover design with two 28-d experimental periods preceded 
by a 14-d adjustment period and separated by a 14-d washout period (Table 3.2, p. 26). 
During the adjustment, experimental, and washout periods, subjects were given a list of foods 
(Table 3.3, p. 27) to eliminate from their diet and foods that were permitted in a given 
amount per day, to decrease their vitamin B-6 intake to approximately 1.0 mg/day (77% of 
the R.DA). After the 14-d adjustment period, subjects were randomly assigned to dairy milk 
(A&E, Des Moines, IA) or soymilk (White Wave, Broomfield, Colorado) treatment for the 
first experimental period. During this 28-d period, subjects consumed 4 cups per day of either 
dairy milk or soymilk, which provided approximately 0.4 mg vitamin B-6 per day (31 % of 
the RDA) in addition to their usual diet while following the food list protocol. The nutrient 
composition of soymilk and cow's milk provided is listed in Table 3.4 (p. 28). Experimental 
diet was intended to bring the subjects' total daily intake close to the Recommended Dietary 
Allowance for vitamin B-6 (1.3 mg/d). A 14-d washout period followed, after which subjects 
crossed over to the other group and consumed either dairy milk or soymilk for the second 
28-d experimental period. On day 28 of each experimental period, subjects were given a 
methionine (L-methionine; Sigma, Saint Louis, MO) load (0.1 g /kg body wt), after fasting 
blood had been taken. 
Diet 
The research team instructed the subjects to follow the diet protocol throughout the 
study. The two types of milk were purchased at a local grocery store and distributed to 
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Table 3.1. Descriptive characteristics of subjects 
Weight
Subjects Age Height Initial Final BMI I Ethnicity 
y m kg kg kg/m J
1 37 1.73 81.9 83.3 27.5 Caucasian 
2 40 1.68 94.5 95.0 33.6 Caucasian 
3 41 1.65 102.6 104.0 37.6 Caucasian 
4 47 1.65 67.5 67.5 24.8 African 
5 52 1.52 61.7 5 8.5 26.5 Caucasian 
6 51 1.59 56.7 56.7 22.5 Caucasian 
7 39 1.77 104.0 96.3 33.4 Caucasian 
8 42 1.68 80.1 77.4 28.5 Caucasian 
9 39 1.85 73.8 72.5 21.5 Caucasian 
10 44 1.65 67.5 64.8 24.8 Caucasian 
11 36 1.68 82.8 84.2 29.5 Caucasian 
12 43 1.73 139.5 138.6 46.8 Caucasian 
13 44 1.63 71.1 71.6 26.9 Asian 
14 3 8 1.73 67.1 66.6 22.5 Caucasian 
15 3 8 l .70 74.7 75.6 25.8 Caucasian 
16 37 1.65 67.5 67.5 24.8 Caucasian 
Mean~SD 41.8 4.9 1.68 0.07 80.8 20.8 80.0 20.7 28.5 6.6 
l Initial body mass index 
Table 3.2. Experimental design 
Period 
Length 
(days) 
Diet 
Adjustment 14 Self-selected, using food list - no dairy milk or soymilk 
Experimental period 1 28 Self-selected, using food list plus 4 cups dairy milk or soymilk 
Washout 14 Self-selected, using food list - no dairy milk or soymilk 
Experimental period 2 28 Self-selected, using food list plus 4 cups dairy milk or soymilk 
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Table 3.3. List of prohibited foods and foods permitted only in designated amounts 
Prohibited foods: 
Fruits: banana, watermelon, avocado 
Vegetables: potato, squash, sweet potato 
Legumes: soybeans 
Nuts: chestnuts, hazelnuts, pistachios, walnuts 
Seeds: sunflower seeds 
Fish: salmon 
Cereals: fortified cereals not listed below; 
instant oatmeal, cream of wheat, or cream of 
rice 
Dairy milk (yogurt, pudding, ice cream) or 
soy milk other than that provided; other 
dairy not listed below 
Foods permitted in designated amounts: 
Juices: Orange or tomato, l cup(8 fl oz) or less; 
Grape, pineapple or vegetable juice cocktail 
(V-8®), '/2 cup or less; Prune or carrot, '/4 cup 
or less 
Legumes (other than soybeans): '/2 cup or less 
Fruits: Prunes, '/4 cup or less; Dates or raisins, 
pineapple, apricots, melon, grapes, '/z cup or 
less; Mango, '/2 mango 
Greens: Spinach, '/4 cup or less; Turnip greens, 
collards, Chinese cabbage, beet greens, kale, 
mustard greens, cooked cabbage, dandelion 
greens, '/2 cup or less 
Nuts, seeds (other than those prohibited): '/4 
cup or less 
Meat, poultry, fish (other than salmon), 
shellfish: 3 oz. or less 
Vegetables: Mushrooms, kohlrabi, onions, 
cooked carrots, cooked broccoli, bamboo 
shoots, cooked cauliflower, artichokes, 
parsnips, rutabagas, sauerkraut, '/2 cup or less 
Brussels sprouts or peppers, red or green, '/4 
cup or less; Raw carrots, 1 carrot; Cucumber, 
1 cucumber 
Miso: '/z cup or less 
Dairy: Cottage cheese or ricotta cheese, '/2 
cup or less; American pasteurized process 
cheese food, 1 slice; Cheese sauce, '/4 cup or 
less; Cheddar, Colby, mozzarella, muenster, 
provolone or swiss cheese, 1 slice or 1 oz. or 
less; Parmesan cheese, '/4 cup; Crearr~ cheese, 
4 TBS or less 
Cereals permitted (X in designated 
amounts): 
Cold cereal: 
Flavorite® Bite-size shredded wheat *(1'/4 
cups or less); Post® Original shredded wheat 
*(2 biscuits or less); Spoon size shredded 
wheat *(1'/4 cups or less); Weetabix® Whole 
grain cereal *(2 biscuits or less); Arrowhead 
Mills® Amaranth flakes; Health Valley® 
Original oat flakes *(3/4 cup or less); Barbara's 
Bakery® Multigrain shredded spoonfuls; 
Shredded wheat *(2 biscuits or less); Sunbelt 
Snacks and Cereals® Berry basic, Fruit &nut, 
Granola;Kashi®; Seven whole grain & 
sesame; Organic promise; Sweethome® 
Low-fat crunchy muesli; Low-fat granola with 
raisins; Honey oat clusters with almonds; 
Fresh vanilla almond crisp; Quaker® Oats & 
honey (& raisin) granola; Sweet puffs *(1 cup 
or less); Puffed wheat; Puffed rice 
Hot cereal: 
Nabisco® Cream of rice, Cream of wheat 
Stone-buhr® Bran flakes; Kretschmer® Oat 
bran cereal; Quaker® Oat bran cereal; Quick 
or old-fashioned oatmeal; Albers® Hominy 
grits; Krusteaz® Zoom hot wheat cereal 
Wheatena® 
Cereal and snack bars: 
Sunbelt® Chewy granola bar; M&M® Kudos 
bar; Quaker® Granola bar; Nature Valley® 
Granola bar 
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Table 3.4. Average daily nutrient composition of 4 cups (C) milk or soymilk consumed by 16 
subjects during each experimental period 1. 
Nutrient unit 
4 C Plain 4 C Vanilla 
soymilk soymilk 
4C 
Chocolate 
Soymilk 
4 C A&E Fat 
Free Skim Milk 
Total Energy kcal 400 400 560 320 
Total Fat g 16 14 14 0 
Cholesterol mg 0 0 0 <20 
Total Carbohydrate g 32 40 92 92 
Fiber g 4 4 8 0 
Protein g 28 24 20 32 
Vitamin A IU 2000 2000 2000 2000 
Vitamin C mg 0 0 0 4.8 
Calcium mg 1200 1200 1200 1200 
Iron mg 4.3 2 4.3 2 5.7 6 0 
Vitamin D IU 480 480 480 400 
Riboflavin mg 2.04 2.04 2.04 * 1.784 
Folate (DFE2) ,ug 96 96 96 *49 
Vitamin B 12 ,ug 12 12 12 *5.194 
Phosphorus mg 240 *470.4 240 *725.2 
Iodine ,ug 180 NA3 NA3 NA3
Magnesium mg 160 160 * 182.4 * 8 8.2 
Zinc mg 2.4 2.4 2.4 * 8.3 3 
* Vitamin B6 mg 0.392 0.392 0.392 0.363 
*Computer analysis using First DataBank Nutritionist Pro 1~M 
' From manufacturers' food labels or nutritional information 
2 DFE represents dietary folate equivalent 
3 NA represents not available 
subjects prior to each experimental week. Preference for flavors was taken into consideration 
for the soymilk distribution, with plain, vanilla, and chocolate flavor soymilk (White Wave, 
Broomfield, Colorado) provided as options. Cow's milk purchased for the study was fat-free 
skim milk with vitamin A and D added (A & E, Des Moines, IA). 
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Sample collection 
Weights of the subjects were recorded at the beginning and the end of the study. 
Subjects completed 3-d diet records once during the adjustment and washout periods and 
twice during each experimental period in order to assess their total daily intake of vitamin 
B-6 and other nutrients. Nutrient analysis was performed by Food Processor (Version 8.5.0, 
ESHA Research, Salem, Oregon). Missing values in the Food Processor program were filled 
in using the online information from the USDA (United States Department of Agriculture) 
Nutrient Data Laboratory. 
To assess creatinine and 4-PA concentrations, subjects collected three consecutive 
24-h urine collections on days 12-14 of the adjustment, experimental, and washout period, 
and days 26-28 of the experimental periods using toluene as a preservative. Total daily urine 
volume was measured and aliquots of urine were frozen (-20°C) until analysis. Blood was 
drawn from fasting subjects on the morning of day 1 of the adjustment and experimental 
periods, and days 15 and 28 of the experimental periods. A second blood sample was drawn 
six hours after the methionine load on day 28 of the experimental periods. Blood samples 
were collected into heparinized Vacutainer tubes (BD Vacutainer® CPTTM) after an overnight 
fast. Heparinized tubes were immediately placed on ice. After the removal of aliquots of 
whole blood for hematocrit measurements, heparinized tubes were centrifuged (at 4°C) and 
plasma separated, aliquoted, and frozen at -30°C until analysis. 
Sample analyses 
Determination of creatinine and urinary 4-PA quantification: Urine was analyzed for 
creatinine concentration (Pino and Gordnya, 1965) by using a microplate reader procedure. 
This commercial kit (Teco Diagnostics, Anaheim, CA) contained 10 mM picric acid; a 
solution containing 10 mM sodium borate, 240 mM sodium hydroxide, and surfactant; and 
creatinine standard (5.0 mg/dL). creatinine working reagent contained a mixture of equal 
volumes of picric acid and borate buffer. A 1:10 dilution of urine was centrifuged for 5 min 
and 10 µL supernatant was pipetted into each well of a 12 X 8 geometric microplate with 210 
µL creatinine working reagent added to each well. The microplates then were placed in 37°C 
heating water bath for 15 minutes. Absorbance was read at a wavelength of 490 nm by 
microplate reader (Bio-Tek instruments.INC, Winooski, vT). 
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Urinary 4-PA was determined by HPLC with fluorometric detection (Gregory and 
Kirk 1979). The HPLC system (Varian Inc, Palo Alto, CA) consisted of a Model 210 liquid 
chromatograph, Model 410 auto injector, Model 3 63 fluorescence detector, and HPLC 
column (Alltech Econosil C 18 1Oµ 250 X 4.6 mm). Reagents for this assay included: mobile 
phase consisting of 0.34 M K3PO4, pH 2.2, 1.25% acetonitrile, and 5%methanol (V:V:V); 
internal standard prepared using 0.6 µM pyridoxamine dihydrochloride (PM); 4-PA stock 
standard (0.11 µmol/mL) frozen at -30°C; and synthetic urine using a solution of 0.5%urea 
and 0.225% NaCI (W:V). 
Subjects' samples were prepared as follows: 0.05 % of a subj ect's total urine volume 
was mixed with 0.2 mL PM (internal standard) and the total volume brought to 5 mL with 
deionized water. For the standard (0.44 nmol/mL) preparation, 0.1 mL 4-PA stock standard 
was combined with 1.0 mL PM and brought to 25 mL total volume in a volumetric flask with 
synthetic urine. Recovery samples were made as follows: 0.625 mL of 1:10 diluted 4-PA 
stock standard was added to 0.05% total volume of well mixed control urine sample and 
brought to 5 mL with deionized water. The amount of diluted 4-PA was equivalent to an 
added 13.65 µmol 4-PA/d. All samples were assayed in duplicate. The subjects' samples, 
standards, and recovery samples were centrifuged for 10 min, and the supernatants were 
filtered into HPLC sample vials using 0.45 µm nylon syringe filters. All 4-PA samples then 
were injected into HPLC column (Column: Alltech Econosil C 18 1Oµ 250 X 4.6 mm; flow 
rate: 1.9 mL/min; injection volume: 50 µL; run time: 10 min), and quantified by fluorescence 
detection at 320 µm excitation and 425 µm emission wavelengths. Mean recovery of urinary 
4-PA was 101 ~ 5% with a control interassay coefficient of variation of 4.8%. 
Plasma PLP and 4-PA quantification: All regents were analytical grade unless 
otherwise specified. PLP, 4-PA, PMP, PL, PN, PM, and DPN were obtained from Sigma 
Chemical Company (Saint Louis, MO). Three-mL aliquots of 1 mM stock solutions of PLP, 
PM, PN, PMP, PL, 4-PA, and 4-deoxypyridoxine (DPN, internal standard) were stored at 
-20°C. The working standard solutions were prepared daily and further diluted with 
deionized water, DPN, and trichloroacetic acid (TCA) to obtain standards with 12.5, 25, 50, 
100, and 200 nM of each standard. Standards were kept on ice and in the dark. Standards 
were prepared in parallel with the blood samples prior to injection into the HPLC system. 
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Prior to analysis proteins were precipitated with 100% TCA. Plasma samples and standards 
were centrifuged for 3 min, and the supernatants were filtered into HPLC autosampler vials 
through 0.2 µm syringe filter (Fisher, Dubuque, IA). 
Plasma PLP and 4-PA were determined by HPLC with fluorometrac detection 
(Sharma and Dakshanamurta 1992). The analytical HPLC column, Microsorb-MV 100-3 C18, 
100X4.6 mm (Varian, Lake Forest, CA), was protected by use of a guard column, 
Ultrasphere C 18 5 µ, 7.SX 4.6 mm (Varian). Mobile phase A consisted of 0.033 M H; PO4 , 
8.0 mM octane sulfonac acid at pH 2.2, while mobile phase B consisted of 0.033 M H3PO4, 
18% isopropanol at pH 2.2. The pre-column derivitization solution consisted of 1 M 
NaK2PO4 and 2 g/L potassium bisulfate at pH 7.5. The fluorescence detector excitation and 
emission wavelengths were set at 295 nm and 405 nm, respectively. The pump flow was 1.0 
mL/min with a premix of 125 µL sample and 15 µL of 2g/L bisulfate solution and an 
injection volume of 50 µL. The solvent gradients were 0% B to 10%Bin 7.5 man; 10% B to 
40%Bin 7.5 min; 40% B for 7 min; 40% B to 0%Ban 10 min; and 0% B for 10 min for a 
total analysis time of 42 min. To identify and quantify vitamin B-6 metabolite concentrations, 
retention times and peak areas were compared with standards. Plasma PLP and 4-PA 
concentration analyses were performed an duplicate. 
Homocysteine analysis: Chemicals and reagents included 4-fluoro-7-
sulfobenzofurazan (ammonium salt, 0.1 %)(SBD-F), N-acetyl-L-cysteine (2.5 mM), and 
tri-n-butylphosphine purchased from Sigma. Other reagents were of analytical grade. Total 
homocysteine concentration an fasting and post-methaonine Ioad plasma samples from day 28 
of each experimental period was determined using HPLC and fluorescence detection by the 
method described by Ubbink et al. (Durand et al. 1996; Ubbink et al. 1991). The analytical 
HPLC column was Alltech Econosil ODS-2 C 18 5 µ 4.6 X 150 mm. The pump flow was 1.0 
mL/min with an injection volume of 50 µL. The fluorescence detector excitation and 
emission wavelengths were set at 3 85 nm and 515 nm, respectively. The total analysis tame 
was 10 min. For derivitization, plasma (120 µL) mixed with 30 µL of N-acetyl-L-cysteine 
(2.5 mM in 0.9% NaCI and 4 mM EDTA) as internal standard (the internal standard allows 
the rapid separation of plasma total SBD-F-deravatazed thaols with accurate quantification; 
Durand et al. 1996) was incubated with 15 µL 10% tra-n-butylphosphine in 
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dimethylformamide for 30 min at 4°C. The reaction was terminated with 0.6 M ice-cold 
perchloric acid containing 1 mM EDTA (150 µL). Following centrifugation for 10 min, 
supernatants (50 µL) were added to a 185 µL of incubation solution containing borate buffer 
(0.125 M, pH 9.5), sodium hydroxide (1.5 5 M), and 0.05 mg SBD-F. Samples were injected 
onto the HPLC column equilibrated in a mobile phase consisting of 2% methanol in 0.1 M 
sodium acetate/acetic acid solution (pH 4.0). 
Statistical analyses 
Data were analyzed using SAS statistical analysis computer software programs 
(version 9.1; SAS Institute Inc., Cary, NC). Results were expressed as group means and 
standard deviations. Urinary 4-PA was averaged over the last three days of each period before 
performing statistical analyses, to minimize the effect of day-to-day variation. Crossover 
ANOVA test was conducted to test significant effects of dairy milk and soymilk treatments. 
Statistical comparisons were considered significant at P < 0.05. 
CHAPTER 4. RESULTS AND DISCUSSION 
Results 
Eighteen volunteers were initially selected to participate in this study. Fifteen subjects 
were Caucasians, one African (Zambian), one Hispanic (Brazilian), and one Asian 
(Malaysian). One subject dropped out during the washout period (Brazilian), and one 
subject's data were eliminated because of analytical difficulties. Consequently, data from 
these two subjects were eliminated from statistical analyses. 
Subject characteristics 
The means for body weight and hematocrit did not change significantly during the 
study. Their mean body weight was 80.8 ~ 20.8 kg before the study and 80.0 ~ 20.7 kg at the 
end of the study.. Their mean hematocrit was 41 ~ 3 %before the study and 40 ~ 3 % at the 
end of the study. 
Diet 
Dietary intakes (mean ~ SD) during each period of study are listed in Table 4.1 (p. 34) 
and Table 4.2 (p. 35).There were no significant differences in the mean total energy, 
carbohydrate, protein, and total vitamin B-6 intake when cow's milk or soymilk was 
consumed. The mean total fat intake was 13 %higher (9 g/d more) when soymilk was 
consumed (P < 0.01). Twelve of the 16 subjects (75%) had a higher total fat intake during the 
soymilk than during the cow's milk consumption period. Moreover, the mean total vitamin 
B-6-to-protein ratio was 14% higher (0.0025 ing/g greater) when soymilk was consumed (P < 
0.01). Twelve of the 16 subjects (75%) had a higher ratio during the soymilk than during the 
cow's milk consumption period. 
In addition, there were significant differences in the mean total dietary fiber, vitamin 
B-12, and folate (DFE) intakes between the cow's milk and soymilk consumption periods. 
The mean fiber intake was 19 ~ 7 g/d during the cow's milk treatment and 24 ~ 4 g/d during 
the soymilk treatment. The mean fiber intake was 21 %higher (5 g/d more) when soymilk 
was consumed (P =0.017). All subjects except one had a higher fiber intake during the 
soymilk treatment. The mean vitamin B-12 intake was 6.5 ~ 0.8 µg/d during the cow's milk 
treatment and 13.4 ~ 0.9 µg/d during the soymilk treatment. The mean vitamin B-12 intake 
was 52% (6.9 µg/d more) higher during the soymilk treatment (P < 0.0001). All subjects 
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had a higher vitamin B-12 intake during the soymilk treatment. In our study, during both 
treatments, the mean vitamin B-12 intakes were adequate based on its RDA (2.4 µg/d). The 
mean folate intake was 290 ~ 112 µg/d during the cow's milk treatment and 345 ~ 128 µg/d 
during the soymilk treatment. The mean folate intake was 16% (55 µg/d more) higher under 
soymilk treatment (P < 0.01). Fourteen of the 16 subjects (75%) had a higher folate intake 
during the soymilk treatment. In this study, during both treatments, neither of the mean folate 
intakes was above the RDA for folate (400 µg/d). 
Urinary 4-PA status measure 
Most studies to date have expressed urinary 4-PA excretion using 24-h urine 
collections (µmol/d). In our study, the urinary creatinine excretion was measured to 
determine whether the urine sample was a complete 24-h sample. Most of the sample 
collections were determined to be incomplete compared to the expected 24-h urinary 
creatinine values according to height for adult females (Blackburn et al. 1977). Thus, instead 
of using daily urinary 4-PA excretion, a urinary 4-PA-to-creatinine ratio was employed as a 
measurement of vitamin B-6 status in this study. The daily estirr~ated urinary 4-PA excretion 
was calculated using expected 24-h urinary creatinine values based on height for adult 
females (Blackburn et al. 1977). The mean urinary 4-PA-to-creatinine ratio was 4.56 ~ 1.04 
µmol/g when the subjects consumed cow's milk and 3.69 ~ 0.74 µmol/g when they 
consumed soymilk. The mean ratio during the soymilk treatment was 19% (0.87 µmol/g 
lower) lower than during cow's milk treatment (P < 0.001, Figure 4.1; p. 37). The estimated 
mean urinary 4-PA excretion was 4.76 ~ 1.13 µmol/d, representing 61 ~ 16% of the total B-6 
intake (7.88 ~ 1.24 µmol/d) that was excreted as urinary 4-PA when subjects consumed the 
cow's milk and 3.87 ~ 0.84 µmol/d, representing 47 ~ 14% of the total B-6 intake (8.41 ~ 
1.52 µmol/d) excreted as urinary 4-PA when subjects consumed soymilk. The estimated 
mean urinary 4-PA excretion was 19% lower (0.89 µmol/d less) when the soymilk than when 
the cow's milk was consumed (P < 0.001). Fourteen of the 16 subjects (87.5%) excreted less 
4-PA at the end of the soymilk than at the end of the cow's milk consumption period. Urinary 
4-PA excretion < 3.0 µmol/d is considered indicative of inadequate vitamin B-6 status 
(Leklem 1990). By the end of soymilk treatment, only one subject excreted < 3.0 µmol/d, and 
none were by the end of the milk treatment. 
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Figure 4.1 Urinary 4-pyridoxic acid (4-PA) to creatinine ratio in 16 middle aged women who consumed 
4 cups soymilk or cow's milk daily for 28 days. Asterisk (*) denotes means that are significantly different 
between soymilk and cow's mi lk treatments (P < 0.001). 
Plasma PLP and 4-PA status measures 
The mean plasma PLP concentration was 3 6.2 ~ 11.9 nM ~~vhen the subjects 
consumed cow's milk and 32.2 ~ 11.3 nM when they consumed soymilk. Thirteen of thel6 
subjects (81 %) had a lower plasma PLP concentration at the end of the soymilk than at the 
end of the cow's milk consumption period. By the end of cow's milk treatment, six subjects 
(37.5%) had plasma PLP concentrations < 30 nM. By the end of the soymilk treatment, five 
subjects (31 %) had PLP concentrations < 30 nM and three of these subjects were < 20 nM. 
The mean plasma 4-PA concentration was 13.2 ~ 4.5 nM when the subjects consumed 
cow's milk and 10.1 ~ 3.7 nM when they consumed soymilk. The data for this measure were 
from 15 subjects because the plasma 4-PA for one subject was not detectable using our 
methods. The mean plasma 4-PA concentration was 23.5% lower (3.1 nM less) when the 
soymilk than when the cow's milk was consumed (P= 0.001, Figure 4.2; p. 3 8). Thirteen of 
the 15 subjects (86.7%) had a Lower plasma 4-PA concentration at the end of the soymilk than 
at the end of the cow's milk consumption period. 
Plasma homocysteine measures 
The mean pre-methionine load plasma total homocysteine concentration was 7.2 ~ 
1.8 µM when the subjects consumed cow's milk and 7.0 ~ 1.8 µM when they consumed 
soymilk. Nine of the 16 subjects (56%) had a lower pre-methionine load concentration at the 
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Figure 4.2 Plasma 4-pyridoxic acid (4-PA} concentration in 16 middle aged women who consumed 4 
cups soymilk or cow's milk daily for 28 days. Asterisk (*) denotes means that are significantly different 
between soymilk and cow's milk treatments (P = 0.001). 
end of the soymilk than at the end of the cow's milk consumption period. 
The subjects' mean post-methionine load plasma total. homocysteine concentration 
was 24. ~ ~ 7.8 µM when they consumed coveys milk and 26.1 ~ ~ .9 µM when they consumed 
soymilk. Eleven of the 16 subjects (69%) had a higher post-methionine load concentration at 
the end of the soymilk than at the end of the cow's milk consumption period. 
The increase in the mean plasma total homocysteine concentration after a methionine 
load was 17.8 ~ 6.3 µM when the subjects consumed cow's milk and 19.1 ~ 5.2 µM when 
they consumed soymilk. Twelve of the 16 subjects (75%) had a greater increase in plasma 
total homocysteine concentration at the end of the soymilk than at the end of the cow's milk 
consumption period. 
Discussion 
This study evaluated the effects of substituting soymilk for cow's milk on vitamin 
B-6 status in middle aged women (36-52 y; n=16). The unique aspects of this study are: 
first, it was a crossover design with two 28-d experimental periods preceded by a 14-d 
adjustment period and separated by a 14-d washout period. Fourteen days were included to 
separate the experimental periods because previous research has shown it takes about 10-14 
days for all B-6 vitamers to plateau after a change in vitamin B-6 intake (Hansen et al. 1997). 
Secondly, the subjects were following a food list designed to limit their daily vitamin B-6 
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intake to less than 1.0 mg; their daily milk or soymilk intake was intended to bring their daily 
total vitamin B-6 intake to the B-6 RDA (1.3 mg/d) for this age group. No studies have been 
published in healthy middle-aged women who were not B-6 depleted, assessing the effect of 
substituting soy products for animal products on vitamin B-6 status. This study provides data 
on vitamin B-6 status indicator values in middle-aged women consuming self-selected diets 
following a vitamin B-6 restricted food list. Thirdly, the methionine load test was chosen as 
an indirect method to assess status to provide further information of its usefulness as a 
potential indirect indicator of vitamin B-6 status. 
Dietary factors affecting status 
Among several factors that affect vitamin B-6 status, dietary protein has been the 
most frequently considered factor to date. Studies have found that the percentage of dietary 
vitamin B-6 excreted as urinary 4-PA and vitamin B-6 decreases as protein intake increases 
(Miller et al. 1985; Hansen et al. 1996a). A vitamin B-6-to-protein ratio of 0.016 mg/g was 
employed for setting the B-6 RDAs in 1989 (RDA 10th ed.; NRC 1989), although currently 
the RDAs for B-6 are not based on protein intake. The cl~rrent RDA is based on a plasma 
PLP concentration of at least 20 nM because plasma PLP is reflective of tissue stores of 
vitamin B-6 (Institute of Medicine 1998). Data under controlled metabolic conditions 
(depletion/repletion studies) show strong interrelationships between vitamin B-6 status 
indicators and B-6 to protein ratios (Donald et al. 1971; Kretsch et al. 1995). In this study, 
when cow's milk was consumed, the mean (~ SD) ratio was 0.0149 ~ 0.002, which was 
lower than the ratio recommended in 1989; when the soymilk was consumed, the mean (~ 
SD) ratio was 0.0174 ~ 0.0033, which was higher than the ratio recommended in 1989. Thus, 
according to the ratios, we would have expected that during soymilk treatment, subjects had 
better B-6 status. However, the mean values of the status indicators measured indicated 
reduced vitamin B-6 status when soymilk was consumed. 
Pyridoxine glucoside, a unique form of vitamin B-6 presented in plant foods, has 
been found to comprise up to 80% of vitamin B-6 in plant foods. More importantly, PNG has 
been considered a less bioavailable form compared with the other six vitamin B-6 forms that 
are present in both animal and plant foods (Gregory 1991). Hansen et al. (1996b) conducted a 
PNG controlled feeding study in women, investigating the extent to which vitamin B-6 
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bioavailability affects vitamin B-6 status, and thus requirement. These researchers showed 
that women consuming a diet containing a higher percentage of the total vitamin B-6 intake 
as PNG exhibited a decrease in vitamin B-6 status indicators, equal to a loss of 15%-18% of 
the total vitamin B-6 intake. This suggested that the reduced bioavailability of PNG and its 
presence in higher amounts in some diets should be considered during the determination of 
the RDA for vitamin B-6. Some soyfoods that have been analyzed for PNG content have 
been found to contain PNG that contributes 57-67% of the total vitamin B-6 (Leklem 2001). 
There has been no information published regarding the PNG content of soymilk. This study 
provides information regarding bioavailability of vitamin B-6 in soymilk on vitamin B-6 
status when substituting soymilk for cow's milk. While subjects were during the soymilk 
treatment, following a vitamin B-6 restricted food list, their daily soymilk consumption 
contributed a higher percentage of the less bioavailable PNG than while during cow's milk 
treatment. 
An additional issue regarding the effect of substituting soy products for animal 
products on vitamin B-6 status is soy protein versus animal protein. In a rat study, after being 
fed the same vitamin B-6 intake in a B-6 deficient diet for 5 wk and given a tryptophan load, 
rats fed soy protein isolate excreted twice the amount of urinary xanthurenic acid in 24 h 
compared with rats fed casein. Moreover, lower erythrocyte aminotransferase activity also 
indicated reduced vitamin B-6 status in the rats fed soy protein (Lu and Huang 1997). The 
results suggest that the source of dietary protein significantly affected the B-6 status in these 
rats. Therefore, it further suggests that apart from the effect of PNG content in soy, replacing 
milk protein with soy protein may have an additional adverse effect on vitamin B-6 status. 
We expected that a similar diet using cow's milk protein would have produced status 
indicators better than soy protein. In this study, subjects had a mean (LSD) soy protein daily 
intake of 24 ~ 3 g/d, representing 30 ~ 8% of daily total protein intake. We cannot determine 
whether this contributed to the reduced vitamin B-6 status. The amino acid composition 
differences between milk protein (primarily casein) and soy protein might affect vitamin B-6 
status measurement. Ni et al. (1998) indicated that soy protein isolate differs from casein in 
the proportion of methionine (14 vs. 31 g/kg protein). Matthias et al. (1996) showed that oral 
administration of high doses of methionine to normotensive and hypertensive rats resulted in 
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a marked elevation of serum homocysteine (34.2 and 61.0 µM for normotensive and 
hypertensive rats, respectively). Thus, it is expected that the high proportion of methionine in 
casein (milk protein) would result in more homocysteine. In our case, the amino acid 
composition differences between soy protein and casein would affect the increase in plasma 
homocysteine after a methionine load, the indirect vitamin B-6 status indicator chosen. 
Some of the confounding factors that may have affected vitamin B-6 status indicator 
measurements include dietary fiber, vitamin B-12, and folate intakes. There were significant 
differences between the diets during cow's milk and soymilk treatments in dietary fiber, 
vitamin B-12, and folate intakes. The diets when soymilk was consumed had 20.8% higher (P 
=0.0167; 5 g/d more) dietary fiber intake than when cow's milk was consumed. This was 
partially due to the fiber content differences of the commercial cow's milk and soymilk 
chosen. There is no fiber content in cow's milk, whereas there is 4 g in 4 cups plain or vanilla 
flavor soymilk and 8 g in 4 cups chocolate flavor soymilk. Lindberg et al. (1983) found that 
the addition of 15 g of wheat bran (6.4 g dietary fiber) to the diet decreased. the vitamin B-6 
bioavaila~bility modestly (by up to 17%) in 10 men aged 20 to 3 5 years consuming bran and 
nonbran diets, providing 1.69 and 1.66 mg/d vitamin B-6, respectively. Vorster et aI. (1987) 
reported that 7.5 to 19 g of supplemental dietary fiber decreased the plasma PLP and 
pyridoxal concentrations in their subjects, although not significantly. Thus, the higher fiber 
intake during the soymilk consumption period may have contributed to the reduced B-6 
bloavallabllity. 
The vitamin B-12 and folate intakes were significantly higher (P < 0.01) when 
soymilk was consumed. This was the result of the fortification of vitamin B-12 and folate in 
the commercial soymilk chosen. Four cups of cow's milk contain 5.2 µg vitamin B-12 
whereas this is 12 µg for 4 cups of soymilk (56.7% higher in soymilk). As far as folate 
content (daily folate equivalent; µg/d) in the commercial milk, it is 96 µg in 4 cups soymilk, 
whereas is only 49 µg in 4 cups cow's milk (49% higher in soymilk).Vitamin B-12 and folate 
intakes could affect the vitamin B-6 indirect status indicator chosen, altering plasma 
homocysteine concentration after a methionine load. Homocysteine, an intermediate in the 
metabolism of methionine, is eliminated by two metabolic pathways: remethylation and 
transsulfuration. In remethylation pathway, by acquiring a methyl group either from 
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N-S-methyltetrahydrofolate or from betaine, homocysteine is remethylated to methionine. 
The reaction with N-S-methyltetrahydrofolate is vitamin B-12 dependent, whereas the 
reaction with betaine is vitamin B-12 independent. In transsulfuration pathway, homocysteine 
reacts with serine to form cystathionine in an irreversible manner catalyzed by the 
cystathionine ~3-synthase, a PLP- dependent enzyme. cystathionine is then hydrolyzed by a 
second PLP-dependent enzyme, 'y-cystathionane, to form cysteine. Excess homocysteine that 
is not required for methyl transfer is effectively catabolized to cysteine via this 
transsulfuration pathway. Both of these aforementioned metabolic pathways contribute to the 
metabolism of homocysteine. Thus, if either vitamin B-12 or folate inadequacy occurs, 
homocysteine will accumulate, despite vitamin B-6 intake being adequate. According to the 
current RDAs for adults, the vitamin B-12 RDA is 2.4 µg/day and the folate RDA is 400 
µg/day (Institute of Medicine 1998). In our study, during both treatments, the mean vitamin 
B-12 intakes were adequate, whereas neither of the mean folate intakes were above the RDA 
for folate. This may have contributed to the lack of significant difference between the mean 
increases in plasma homocysteine concentration after a methionine load at the end of the: 
cow's milk and soymilk treatments. If folate intakes were adequate, the mean increase in 
plasma homocysteine concentration after a methionine load with soymilk treatment might 
have become significantly greater than with cow's milk treatment. 
Direct measures of vitamin B-6 status 
The major end-product of vitamin B-6 metabolism is 4-pyridoxic acid. Urinary 4-PA 
excretion has been considered a short term indicator of vitamin B-6 status that is directly 
reflective of recent B-6 intake (Leklem 1990). A previous human study conducted by 
Schuster et al. (1984) indicated that expressing urinary 4-PA excretion as the ratio 
4-PA/creatinine is representative of the total 4-PA excretion in 24-h samples. Moreover, their 
results suggest that the 4-PAlcreatinine ratio in random urine samples reflects the total 4-PA 
excretion in a 24-h period. The mean 4-PA-to-creatinine ratio during soymilk treatment was 
significantly lower than during cow's milk treatment (P < 0.001), indicating reduced vitamin 
B-6 status at the end of soymilk treatment. To date, no inadequacy cutoff for 
4-PA-to-creatinine ratio has been established. Hence, we further expressed the ratio as the 
estimated daily urinary 4-PA excretion using the expected 24-h urinary creatinine values 
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based on height for adult females (Blackburn et al. 1977). Thus, we can compare our results 
with the other studies which expressed their results as daily 4-PA excretion, as well as 
compare the individual values with the inadequacy cutoff (< 3 µmol/d; Leklem 1990). The 
individual data for the estimated daily urinary 4-PA concentrations showed urinary 4-PA 
excretion reached values indicative of adequate status in all subjects during both treatments, 
except for one subject who was excreting less than 3 µmol/d (2.6 µmol/d) with a total 
vitamin B-6 intake of 5.92 µrnol/d (1.00 mg/d) during the soymilk treatment. The calculated 
mean estimated daily urinary 4-PA excretion values were in agreement with the mean urinary 
4-PA-to-creatinine ratio that indicated reduced vitamin B-6 status when soymilk was 
consumed (P < 0.001). Because the urinary 4-PA excretion is considered a short term status 
indicator, it best describes how recent dietary intake affects the vitamin B-6 status. Thus, the 
significantly lower mean values at the end of the soymilk treatment strongly support our 
hypothesis that it was the soymilk treatment, the recent dietary intake, that resulted in 
reduced vitamin B-6 status. 
Fasting plasma PLP concentration, the most frequently used direct status indicator, is 
reflective of tissue stores of vitamin B-6 (Leklem 1990). There was no evidence that the 
mean fasting plasma PLP concentration was different when soymilk or cow's milk was 
consumed. The mean values during both treatments were above the recommended cutoff of 
3 0 nM. However, the cutoff values are less useful for comparison of mean values than for the 
comparison of individual data (Hansen et aI. 1997). Notably, when soymilk was consumed, 
three subjects (19%) had a plasma PLP concentration less than 20 nM; their fasting PLP 
concentrations were 12.9, 12.4, and 19.8 nM, with total vitamin B-6 intakes of 1.00 (5.92 
µmol/d), 1.3 5 (8 µmol/d), and 0.92 (5.42 µmol/d) mg/d, respectively, whereas during cow's 
milk treatment, no subjects had a value below 20 nM. Moreover, no evidence of significance 
was shown for the mean plasma PLP between the treatments could be due that, compared 
with the urinary 4-PA excretion, the plasma PLP is relatively more reflective of long-term 
vitamin B-6 status. Thus, in a short-term study (28 d), it might not change as rapidly as the 
urinary 4-PA excretion in response to the treatments. 
There has been limited research regarding the usefulness of fasting plasma 4-PA 
concentration as an index of vitamin B-6 status. The measurement of fasting plasma 4-PA 
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concentration in our study provides further information of its usefulness as a potential direct 
indicator of vitamin B-6 status. The mean fasting plasma 4-PA concentration was 
significantly lower during the soymilk than during the cow's milk treatment (P = 0.001). The 
lower plasma 4-PA concentration when soymilk was consumed may be reflective of the fact 
that less vitamin B-6 was being metabolized to 4-PA because less was available in soymilk. 
These results suggest reduced vitamin B-6 status at the end of the soymilk treatment, 
reflected by the urinary 4-PA and plasma 4-PA measurements. The results further suggest that 
plasma 4-PA may be a valid vitamin B-6 status indicator. Further research investigating the 
usefulness of plasma 4-PA as a direct status indicator of vitamin B-6 is necessary. 
Indirect measures of vitamin B-6 status 
Methionine load test was chosen as the indirect measure to assess vitamin B-6 status 
in our study. Because vitamin B-6 (PLP) plays a role in the catabolism of homocysteine to 
cysteine, an increase in plasma homocysteine concentration after a methionine load has been 
considered useful in assessing vitamin B-6 status. Limited information about the usefulness 
of this l~neasure as a potential indirect indicator of vitamin B-6 status is available, whereas 
our study provides information convincing evidence. 
Some dietary factors may have affected the results, including: folate intake which is 
an important potential contributor to the insignificance in the means of increase in the plasma 
homocysteine concentration after a methionine load. During both treatments the mean folate 
intakes were slightly below the current RDA for folate (400 µg/d), although they were both 
above the RDA for folate in 1989 (200 µg/d). The mean folate intake was 16% higher (55 
µg/d more) during soymilk treatment. Due to the role that folate plays in homocysteine 
remethylation, inadequate intakes of folate might have resulted in the decreased elimination 
of homocysteine via the remethylation pathway involved in both folate and vitamin B-12, 
despite adequate vitamin B-6 intake that ensured the catabolism of homocysteine to cysteine 
via transsulfuration. If these participants had experienced an improved folate status (~ 400 
µg/d) during the soymilk treatment, the change in plasma homocysteine after the methionine 
load might have become significant. Additionally, we may have reported a significant 
increase in plasma homocysteine concentration after a methionine load during the soymilk 
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versus cow's milk treatment if the study period was longer (>28 d), the diets more rigidly 
controlled, and our sample size was larger (n >16). 
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CHAPTER 5. SUMMARY AND CONCLUSIONS 
This study was conducted to determine the effect of substituting soymilk for cow's 
milk on vitamin B-6 status in middle aged women. Our hypotheses were that women who 
substituted soymilk for cow's milk would have decreased concentrations of plasma PLP and 
4-PA, and urinary 4-PA, and increases in plasma homocysteine concentration after a 
methionine load. 
Throughout the study, our subjects followed a vitamin B-6 restricted diet designed to 
limit their daily vitamin B-6 to less than 1.0 mg, apart from the approximately 0.4 mg of 
daily vitamin B-6 intake either from soymilk or cow's milk provided by the investigators. 
During either the cow's milk or soymilk treatment, the mean vitamin B-6 intake was above 
the RDA for vitamin B-6. Compared with the recommended vitamin B-6-to-protein ratio by 
the DRI committee in 1989 (0.016 mg/g protein); however, the mean ratio was lower during 
the cow's milk treatment, whereas it was higher during the soymilk treatment. After 28 d of 
soymilk consumption, our subjects had significantly lower mean urinary 4-PA-to-creatinine 
ratio, estimated daily urinary 4-PA excretion, and plasma 4-PA concentrations compared to 
the end of 28 d of cow's milk consumption. These results indicate reduced vitamin B-6 status 
at the end of soymilk treatment. There was no evidence of differences in either the mean 
plasma PLP (P = 0.107) or the mean increase in plasma homocysteine concentration after a 
methionine load (P = 0.316) between the treatments. With longer study periods, more rigidly 
controlled diets, and larger sample size, it may be possible that the difference would become 
significant. The reduced vitamin status during soymilk treatment may be due to the PNG 
content in soymilk. Pyridoxine glucoside, a form of B-6 with a reported 58% bioavailability 
compared with the other six commonly consumed forms of B-6 (Gregory et al. 1991), is only 
present in plant foods. Thus, the relatively higher percentage of vitamin B-6 as PNG in the 
diet when soymilk was consumed may account partially for the reduced status indicator 
measurements we have reported. The amount of four cups of soymilk that has contributed to 
0.4 mg of vitamin B-6 daily intake was chosen in our study because the FDA-approved 
health claim states that 25 g of soy protein daily has a significant cholesterol lowering effect 
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and the amount of soy protein in the commercial soymilk chosen provided approximately 
that amount daily. 
For determining adequacy of vitamin B-6 status, a functional measure related to a 
specific health outcome ideally would be the best status measure. Plasma PLP concentration 
was chosen as the standard for adequate status because this measure appears to be reflective 
of tissue stores (Lui et al. 1985). Without evidence Linking a particular concentration to 
favorable or unfavorable health outcomes, a fasting plasma PLP concentration of 20 nM was 
chosen as the standard for adequacy by the DRI committee in 1998. However, other 
investigators consider a higher concentration of >3 0 nM for adequacy based on results from 
human feeding studies (Leklem 1990; Hansen et al. 2001). The vitamin B-6 RDA was 
calculated based on an EAR of 1.1 mg/d, the intake of vitamin B-6 required for a plasma PLP 
concentration of 20 nM (Institute of Medicine 1998). Findings from our study showed that 
based on the 20 nM cutoff, all subjects exhibited adequate status when cow's milk was 
consumed whereas during soymilk treatment, 19% (3 of 16) had an inadequate value. 
However, considering 3 0 nM cutoff., 3 7.5 % (6 of 16} read inadequate status when they 
consumed cow's milk and 31.3 % (5 of 16) exhibited inadequate status during soymilk 
treatment. 
Urinary 4-PA excretion, as a short-term vitamin B-6 status indicator, is reflective of 
recent vitamin B-6 intake, with a value of less than 3 µmol/d considered inadequate (Leklem 
1999). In this study, when soymilk was consumed, there was one subject who had a urinary 
4-PA excretion value that fell below 3 µmol/d, whereas no subjects fell below this cutoff 
when cow's milk was consumed. Moreover, as urinary 4-PA excretion reflects the recent 
vitamin B-6 intake, the significantly Lower mean urinary 4-PA-to-creatinine ratio and 
estimated urinary 4-PA excretion at the end of the soymilk treatment, strongly support our 
hypothesis that it was the soymilk treatment, the recent diets, that resulted in the reduced 
status of this vitamin B-6 indicator compared to the end of cow's milk treatment. 
There are several vitamin B-6 metabolites that do not have an established, defined 
status indicator concentration, such as plasma PL and 4-SPA. Thus, it is difficult to conduct 
status assessment when considering them as biomarkers. The mean plasma 4-PA 
concentration was significantly lower during the soymilk: treatment than that during the cow's 
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milk treatment (P = 0.001). A lower plasma 4-PA concentration when soymilk was consumed 
maybe reflects that less vitamin B-6 was available for metabolism. 
The methionine load test was chosen as the indirect status measurement. The 
methionine load given in this study was 0.1 g/kg body weight, which was approximately 3 to 
5 times higher than the amount of average methionine intake from a typical diet. In this study, 
this measure showed our expected greater increase (albeit not significantly) in mean plasma 
total homocysteine concentration after a methionine load for the soymilk compared to cow's 
milk treatment. The relatively short study period (28 d), small sample size (n = 16), 
uncontrolled diets (self-selected diets) might have contributed to the insignificant increase for 
this measure. Based on our results, study design employing a longer period, larger sample 
size, and a more rigidly controlled diet would be warranted to assess the usefulness of this 
measure as a potential indirect or functional vitamin B-6 status indicator. 
In summary, a diet composed of natural foods with a relatively high amount of PNG 
content contributed by 4 cups daily of soymilk reduced the urinary 4-PA-to-creatinine ratio, 
estimated urinary 4-PA excretion, and plasma 4-PA concentrations in middle aged women 
after 28 days. When soymilk was consumed, subjects had a significantly higher mean dietary 
vitamin B-6-to-protein ratio. ~1Ve would expect the vitamin B-6 status measurements to 
improve during soymilk treatment compared to cow's milk treatment. However, the results 
showed reduced vitamin B-6 status at the end of soymilk treatment. The decrease in vitamin 
B-6 status indicators when soymilk was consumed suggested that substituting soymilk for 
cow's milk had an adverse effect on vitamin B-6 status in middle aged women as reflected by 
the reduced status indicators at the end of soymilk consumption. All of the findings indicate 
that vitamin B-6 in soymilk is less bioavailable than from cow's milk. The results of our 
study further suggest that the RDA for vitamin B-6 should take into consideration the 
reduced vitamin B-6 bioavailability of a high PNG content diet. The long-term effect of 
consuming a high PNG content diet on vitamin B-6 status needs to be investigated. The 
long-term consumption of high PNG content diets on vitamin B-6 status may greatly affect 
people with marginal intakes or consuming diets in which most of the B-6 intake is from 
plant foods. Thus, future research determining the quantitative importance of the effect of 
vitamin B-6 intake from PNG is needed. 
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